








































































Application of surfaced-deacetylated chitin nanofibers to medical and pharmaceutical fields 
Ryo Tabuchi 
 
Chitin, a linear polymer composed of β (1-4)-N-acetyl-D-glucosamine unit, has been proposed for 
use as a functional material in medical and pharmaceutical fields, because of its biocompatibility, 
biodegradability, the absence of toxicity, adsorption properties and free radical scavenging activities. 
Recently, surface-deacetylated chitin nanofibers (SDACNFs) were prepared by Ifuku et al., by partial 
deacetylation of the amide groups on the surface of the chitin nanofibers. SDACNFs have various 
physiological activities such as lipid absorption inhibitory and wound healing effects etc. However, our 
knowledge on medical uses of SDACNFs is currently limited. Therefore, we investigated the application 
of SDACNFs to medical and pharmaceutical fields. 
 
1) Renoprotective and antioxidant activity of SDACNFs in nephrectomized rats 
 
In this study, we described that SDACNFs are more effective in decreasing renal injury and oxidative 
stress than deacetylated chitin powder (DAC) in 5/6 nephrectomized rats. An oral administration of low 
doses of SDACNFs over a 4 week period resulted in significant decreases in serum indoxyl sulfate, 
creatinine and urea nitrogen levels, compared with a similar treatment with DAC or AST-120. The 
SDACNFs treatment also resulted in an increase in antioxidant potential, compared with that for DAC 
or AST-120. Immunohistochemical analyses also demonstrated that SDACNFs treated nephrectomized 
rats showed a decrease in the amount of accumulated 8-OHdG compared with the non-treated group. In 
in vitro studies, the interaction of SDACNFs with a uremic toxin, indole molecule, was much higher 
than that for DAC. These results suggested that the ingestion of SDACNFs results in a significant 
reduction in the levels of pro-oxidants, such as uremic toxins, in the gastrointestinal tract, thereby 
inhibiting the subsequent development of oxidative stress in the systemic circulation. 
 
2) Application of SDACNFs sponges for the wound healing 
 
 Beschitin® is a commercially available chitin-containing wound dressing and widely used in clinical 
fields. In this study, we described that SDACNFs sponges are more effective in wound healing of model 
rats than Beschitin®. The wound areas of the excision rats were significantly decreased by the application 
of SDACNFs sponge groups, compared with those of the non-treated or Beschitin® group, on days 4, 8, 
10, 12 and 14. In histopathological studies, the complete skin generation including re-epithelium was 
observed only in SDACNFs sponge groups, whereas the re-epithelium generation was not adequate in 
the non-treated and Beschitin® groups. SDACNFs sponges had a higher water-absorbing property than 
Beschitin®, which may contribute to the more effective wound healing. The results indicated that 
SDACNFs sponges were superior to Beschitin® in the wound healing effect. 
 
3) SDACNFs reinforced with sulfobutyl ether β-cyclodextrin gel containing prednisolone as potential 
therapy for inflammatory bowel disease 
 
SDACNFs reinforced with a sulfobutyl ether β-cyclodextrin (SBE-β-CyD) gel were developed to 
obtain a controlled release carrier of prednisolone (PD) for the treatment of colitis. PD was released 
slowly from the gel at both pH 1.2 and 6.8. The in vitro slow release of PD from the SDACNFs/SBE-β-
CyD gel was reflected in the in vivo absorption of the drug after oral administration to rats. These results 
suggested that a simple gel composed of a mixture of SDACNFs and SBE-β-CyD has the potential for 
use in the controlled release of PD. We also evaluated the therapeutic effects of the SDACNFs/SBE-β-
CyD gel containing PD on dextran sulfate sodium (DSS)-induced colitis model mice. The administration 
of the SDACNFs/SBE-β-CyD gel at intervals of 3 days from the beginning of the DSS treatment resulted 
in a significant improvement, not only in colitis symptoms but also histopathological changes in colon 
tissue. In addition, the therapeutic effects of the SDACNFs/SBE-β-CyD gel on colitis can be attributed 
to decreased levels of neutrophil infiltration and the development of oxidative stress. These efficacy 
profiles of the SDACNFs/SBE-β-CyD gel containing PD suggested that it has the potential for use in 
the treatment of, not only colitis, but also a variety of other disorders associated with inflammation and 
oxidative injuries.  
 
 The prophylaxis or therapy associated with combined uses of drugs with SDACNFs will give a new 
strategy for antioxidant treatments in several types of diseases including renal failure, because the 
antioxidant effect of SDACNFs is unique and differs from that of other conventional antioxidants. 
Further, SDACNFs/SBE-β-CyD gels are useful for preparing homogeneous high-content gels capable 
of carrying poorly water-soluble drugs. In conclusion, SDACNFs or their derivatives could be used for 
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AUC ݄஦ೳౕۄતԾ໚੷ Area under the blood concentration- 
  time curve 
BA ਫ਼෼ָదཤ༽೵ Bioavailability 
BUN ೚ો஢ો Blood urea nitrogen 
CRF ອ੓ਝ෈સ Chronic renal failure 
CNFs ΫοϱψόϓΟ΢ώʖ Chitin nanofibers 
DAC ୦ΠιοϩԿΫοϱ Deacetylated chitin 
DSS υΫηφϧϱོ࢐ψφϨΤϞ Dextran sulfate sodium 
DM-β-CyD ζϟοϩ-β-εέϫυΫηφϨϱ Dimethyl-β-cyclodextrin 
HB-β-CyD ϐχϫΫεϔοϩ-β-εέϫυΫηφϨϱ Hydroxybutyl-β-cyclodextrin 
Hb ϖϠήϫϑϱ Hemoglobin 
HP-β-CyD ϐχϫΫεϕϫϒϩ-β-εέϫυΫηφϨϱ Hydroxypropyl-β-cyclodextrin 
IS ΢ϱχΫεϩོ࢐ Indoxyl sulfate 
MRI ࣕـڠ໒ժ଀๑ Magnetic resonance imaging 
MPO ϝΦϫϘϩΨΫεξʖκ Myeloperoxidase 
MRT ฑۋ଼ཻ࣎ؔ Mean retention time 
SDACNFs න໚୦ΠιοϩԿΫοϱψόϓΟ΢ώʖ Surface-deacetylated chitin 
                                                     nanofibers 
SBE-β-CyD ηϩϙϔοϩΦʖτϩ-β-εέϫυΫηφϨϱ Sulfobutyl ether-β-cyclodextrin 
PAO ݄ᕸ߇࢐Կ೵ Plasma antioxidant potential 
PASઝ৯ գϦΤો࢐ερϓઝ৯ Periodic acid Schiff stain 
PD ϕϪχωμϫϱ Prednisolone 
RBC ੼݄ځ Red blood cell 
PLT ݄ঘ൚ Platelet 
WBC പ݄ځ White blood cell 










୊ 1হ ॻݶʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ1 
 
୊ 2 হ 5/6 ਝଃఢड़ϧρφͶ͕͜Ζ SDACNFs ͹ਝ෈સ਒ߨ͕Γ;࢐ԿηφϪη͹ཊ੏Ͷ
ؖͤΖݗ౾ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ6 
 
୊ 1ઇ ঄ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ6 
୊ 2ઇ ອ੓ਝ෈સͶଲͤΖ SDACNFs ͹༙༽੓඲Ճʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ 8 
୊ 1ߴ In vitro Ͷ͕͜Ζ SDACNFs ͹΢ϱχʖϩٷ஥೵඲Ճʀʀʀʀʀʀʀʀʀʀʀ8 
୊̐ߴ SDACNFs ͹ਝฯޤ͕Γ;߇࢐ԿްՎʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ9 
 ୊ 3ߴ SDACNFs Ν౦༫ͪ͢ϧρφ͹ਝૌ৭͹؏ࡱʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ11 
୊ 3ઇ ߡࡱʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ13 
୊ 4ઇ ঘׇʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ15 
 
୊ 3হ SDACNFs ηϛϱζ͹૓উ࣑ྏͶؖͤΖݗ౾ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ16 
  
୊ 1ઇ ঄ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ16 
 ୊ 2ઇ SDACNFs ηϛϱζ͹༙༽੓඲Ճʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ17 
  ୊ 1ߴ SDACNFs ηϛϱζ͹௒੣ͳන໚؏ࡱʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ17 
  ୊ 2ߴ SDACNFs ηϛϱζ͹ٷਭ੓඲Ճʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ18 
  ୊ 3ߴ SDACNFs ηϛϱζ͹૓উ࣑ྏްՎʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ20 
 ୊ 3ઇ ߡࡱʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ22 
 ୊ 4ઇ ঘׇʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ24 
 
୊ 4হ  ϕϪχωμϫϱ (PD) ؜༙ SDACNFs/ηϩϙϔοϩΦʖτϩ-β-εέϫυΫηφϨϱ 
(SBE-β-CyD) ΰϩ  (PD ؜༙ΰϩ) ͹  DSS ༢൅௷ ੓୉ௐԎ࣑ྏͶؖͤΖݗ
౾ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ25 
  
୊ 1ઇ ঄ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ25 
 ୊ 2ઇ SDACNFs/SBE-β-CyD ΰϩ͹௒੣ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ26 
  ୊ 1ߴ SDACNFs/֦झ CyD ΰϩ͹௒੣ʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ26 
  ୊ 2ߴ SDACNFs/SBE-CyD ΰϩ͹෼੓඲Ճʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ27 
 ୊ 3ઇ PD ؜༙ SDACNFs/SBE-β-CyD ΰϩ͹༙༽੓඲Ճʀʀ ʀʀʀʀʀʀʀʀʀʀʀ29 
  ୊ 1ߴ PD ؜༙ΰϩ͹௒੣ͳΰϩ͹کౕ͕Γ;ΰϩ͖Δ͹ PD ͹๎ड़඲Ճ ʀʀʀʀ29 
  ୊ 2ߴ PD ؜༙ΰϩ͹ PD ର಼ಊସͳভԿ؇಼଼ཻ੓඲Ճʀʀʀʀʀʀʀʀʀʀʀʀ31 
 ୊ 4ઇ PD ؜༙ΰϩ͹ DSS ༢൅௷ ੓୉ௐԎ࣑ྏްՎʀʀʀʀʀʀʀʀʀʀʀʀʀʀ34 
  ୊ 1ߴ DAI ηαΠͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճʀʀʀʀʀʀʀʀʀʀ34 
  ୊ 2ߴ ୉ௐૌ৭͕Γ;୉ௐ MPO ׈੓ͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճʀ 35  
  ୊ 3ߴ ݄ځ੔෾͕Γ;ᡰଃ॑ྖͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճʀʀʀʀʀ37 
 ୊ 5ઇ ߡࡱʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ38 
୊ 6ઇ ঘׇʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀʀ41 
 



























































LPS ࢙ܻͶΓΕϜέϫϓΟʖζ͖Δࢊਫ਼͠ΗΖԎ঳੓γ΢φΩ΢ϱͲ͍Ζ TNF-α Ώ IL-6 










Γ; ABTS ϧζΩϩΝ༽͏ͱݗ౾͢ 7–9)ɼͨ͹߇࢐ԿްՎͺɼϑνϝϱ C (VC) Ͷͺٶͻ͵
͏΍͹͹ɼఁ෾ࢢ͹ΫφγϱΆʹ߶͚ɼVC  > Ϋφγϱ >> ήϩαγϝϱ >>  N-Πιοϩ
ήϩαγϝϱ͹ॳͲ͍Ζ͞ͳΝๅࠄͪ͢ɽΉͪɼΫφγϱ͹ϧζΩϩভڊͶͺΠϝόخ͹ଚ
ࡑ͗॑གྷͲ͍Ζ͞ͳ͗ࣖࠨ͠Ηͪɽ͠ΔͶɼΫφγϱͺ in vitro ͫ͜Ͳ͵͚ in vivo Ͳ΍߇࢐
ԿްՎΝ൅ضͤΖ͞ͳΝझʓ͹ಊ෼ϠυϩΏಃੵ׳ंͶ͕͏ͱ໎Δ͖Ͷͪ͢ 18)ɽΫφγϱ͗
ਫ਼ର಼Ͳ߇࢐ԿްՎΝࣖͤϟΩωθϞͳ͢ͱɼఁ෾ࢢΫφγϱ (෾ࢢྖ 3 kDa ҐԾ) ͹৖߻
ͺɼভԿ؇͖Δٷफ͠Ηͱસਐ१؂ͶΓΕ௜ંద͵߇࢐ԿްՎΝࣖ͢ɼҲ๏ɼভԿ؇͖Δٷ










ʖԿͤΖٗढ़ཱི֮͗͠ΗͪɽιϩϫʖηψόϓΟ΢ώʖͺɼర߱͹ 1/5͹ܲ͠Ͳɼͨ ͹ 5ഔҐ
৏͹کౕͲ͍Εɼત೦๴௃ܐ਼ͺΪϧη͹ 1/50ҐԾͳ༑Ηͪ෼੓Ν༙͢ͱ͏Ζ 20)ɽ͠ΔͶɼ












γϱΓΕ΍߶͏ਫ਼ཀྵ׈੓Ν࣍ͯɽࣆࣰɼAzuma ΔͺɼCNFs ΝυΫηφϧϱོ࢐ψφϨΤϞ 
(dextran sulfate sodium, DSS) ༢൅௷ ੓୉ௐԎϠυϩϜΤηͶԢ༽ͪ݃͢ՎɼψόϓΟ΢ώʖ
Կ͢ͱ͏͵͏Ϋοϱฆ຦ΓΕ΍༑Ηͪ୉ௐԎཊ੏ްՎΝࣖͤ͞ͳΝๅࠄ͢ͱ͏Ζ 28)ɽ͠ΔͶɼ
࠹ۛ Ifuku Δͺ CNFs ͹න໚͹ΊΝ୦ΠιοϩԿ (༁ 20 %) ͢ɼΠϝόخ͹੫ుదൕ൅ྙͶ
ΓΕɼ෾ࢆ੓ΝΓΕ޴৏ͦͪ͠௜ܚ 10-20 nm ͹න໚୦ΠιοϩԿΫοϱψόϓΟ΢ώʖ 














Fig. 2. Appearance of CNFs and SDACNFs. 
CNFs : S. Ifuku, Molecules, 19, 18367-18380 (2014). 
SDACNFs : M. Egusa et al., Int. J. Mol. Sci., 16, 26202–26210 (2015). 
 
͞͹෾ࢆ੓͹޴৏ͪ͢ SDACNFs ͺ CNFs ΓΕ΍૓উ࣑༌ଇ਒ްՎ 4)ɼ߇ۗްՎ 1)ɼ߇
͗Ξࡐ༢൅ҥௐ্֒ཊ੏ްՎ 30)ɼࢹ࣯ٷफཊ੏ްՎ 31) ͗޴৏ͤΖ͞ͳ͗ๅࠄ͠Ηͱ͏Ζɽ
ྭ͓ͻɼIzumi ΔͺɼSDACNFs ͗૓উ໚͹Ԏ঳Νཊ੏͢ɼαϧʖΰϱ߻੔Νଇ਒ͤΖ͞ͳͲ
૓উ࣑༌ଇ਒ްՎΝࣖ͢ɼ͞͹ްՎͺ୦ΠιοϩԿౕ͹ఁ͏ CNFs ΓΕ΍߶͏͞ͳΝๅࠄ͢
ͱ͏Ζ 4)ɽΉͪɼEgusa ΔͺɼSDACNFs ͗୦ΠιοϩԿౕ͹ఁ͏ CNFs ͳർֳ͢ͱ߶͏߇ਇ
ۗ׈੓Ν࣍ͯ͞ͳΝๅࠄ͢ͱ͏Ζ 1)ɽψόϓΟ΢ώʖͶ͕͜Ζ߇ۗ׈੓ϟΩωθϞͺɼॉ෾
Ͷͺմ໎͠Ηͱ͏͵͏͗ɼ৏फ़ͪ͢Γ͑͵ϟΩωθϞ͗ψόϓΟ΢ώʖͲ΍ً͞Ζͳਬࡱ͠
ΗΖɽ͠ΔͶɼKoizumi ΔͺɼSDACNFs ͗ɼ߇͗ΞࡐͲ͍Ζ 5-ϓϩΨϫΤϧεϩ (5-FU) Ͷ
ΓΕ༢൅͠ΗΖҥௐ্֒Ͷଲ͢ͱ༩๹ްՎΝࣖͤ͞ͳΝๅࠄ͢ͱ͏Ζ 30)ɽ5-FU ͺҥ͗Ξɼ
،ଃ͗Ξɼ೗͗Ξ౵Ͷ෱߁͚༽͏ΔΗΖ߇͗ΞࡐͲ͍Ζ͗ɼ෯ࡠ༽ͳ͢ͱҥௐ্֒Ν༢൅ͤ















Ͳͺɼອ੓ਝ෈સͶ͕͜Ζ೚ಡ঳෼࣯͹ҲͯͲ͍Ζ IS Ͷ஥໪͢ɼIS ͹઴ۨରͲ͍Ζ΢ϱχ
ʖϩ͹ SDACNFs ΃͹ٷ஥͕Γ; 5/6 ਝଃఢड़ϧρφͶ͕͜Ζ SDACNFs ͹ਝฯޤްՎͶ
ͯ͏ͱਝ෈સ࣑ྏ༂Ͳ͍Ζ AST-120 (έϪϟζϱ®) ͕Γ;ψόϓΟ΢ώʖԿ͢ͱ͏͵͏୦Π
ιοϩԿΫοϱ (deacetylated chitin, DAC) ͳർֳݗ౾ͪ͢ɽ୊ 3হͲͺɼSDACNFsΝ౜݃ף
૫͢ͱηϛϱζয়ͶՅ޽͢ɼ͞͹ SDACNFs ηϛϱζ͹ϧρφ૓উϠυϩͶ͕͜Ζ૓উ࣑༌




੓εέϫυΫηφϨϱ (CyD) 33,34) ༢಍ରͲ͍ΖηϩϙϔοϩΦʖτϩ-β-εέϫυΫηφϨ
ϱ (SBE-β-CyD) Ͷ஥໪͢ɼ߶کౕ͹ SDACNFs/SBE-β-CyD ΰϩΝ௒੣ͪ͢ 35)ɽ͠ ΔͶɼCyD 
͹࣍ͯೋਭ༻੓༂෼༻մࡠ༽Νཤ༽͢ͱɼϠυϩ༂෼ϕϪχωμϫϱ (PD) Ν෩೘ͪ͢ΰϩ












୊ 2হ 5/6ਝଃఢड़ϧρφͶ͕͜Ζ SDACNFs ͹ਝ෈સ਒ߨ͕Γ;࢐ԿηφϪη͹ཊ੏Ͷؖ
ͤΖݗ౾ 
 
୊ 1ઇ ঄ 
 
ਝ෈સͺɼࢵځରΏ೚ࡋ؇্͗֒Νण͜Ζ͞ͳͲਝଃؽ೵͗ఁԾͤΖබସͲ͍Εɼٺଐ
Ͷਝଃؽ೵͗ఁԾͤΖٺ੓ਝ෈સ (Acute renal failure, ARF) ͳௗ͏೧݆Ν͖͜ͱঅʓͶਝଃ















࣑ྏ๏ਓ͹Ҳͯͳߡ͓ΔΗͱ͏Ζ (Fig. 3)ɽ 










ͱ͏Ζ 12)ɽ͠ ΔͶ࠹ۛɼಃੵ஦͹׳ं 11ྭΝଲেͳ͢ͱɼΫφγϱઃखͶ൒͑ਝ্֒͹਒ߨ
ౕٶ;࢐ԿηφϪη͹รಊͶͯ͏ͱ௒ࠬͪ݃͢ՎɼΫφγϱઃख઴ͳർֳ͢ͱ༙қ͵݄ੜϨ





Ζ͞ͳͲɼਝฯޤްՎ͹޴৏͗غଶͲ͘Ζ͹Ͳͺ͵͏͖ͳߡ͓ɼSDACNFs ͹ in vitroͶ͕͜













Fig. 3. Proposed mechanism for the renal protective and antioxidative effect by SDACNFs. 
































୊ 2ઇ ອ੓ਝ෈સͶଲͤΖ SDACNFs ͹༙༽੓඲Ճ 
 
୊ 1ߴ In vitro Ͷ͕͜Ζ SDACNFs ͹΢ϱχʖϩٷ஥೵඲Ճ 
 
In vitro Ͷ͕͜Ζ SDACNFs ͹΢ϱχʖϩٷ஥೵Ͷͯ͏ͱɼψόϓΟ΢ώʖͶմࡇͤΖ











Fig. 4. Adsorption ability of SDACNFs, DAC, AST-120 and CNFs against indole after 1hr (A) and 24hr 
(B). Results are shown for SDACNFs (black circle), DAC (white circle), AST-120 (gray circle), CNFs 
(white square). 
 
SDACNFsɼDACɼCNFsɼAST-120 ͹ 1͕࣎ؔΓ; 24࣎ؔޛ͹΢ϱχʖϩٷ஥Νർֳ͢
ͪ݃ՎɼSDACNFs ͹΢ϱχʖϩٷ஥ͺೳౕғଚదͶଁ୉͢ɼψόϓΟ΢ώʖԿ͢ͱ͏͵͏ 
DAC ͕Γ;୦ΠιοϩԿౕ͗ 1%ఖౕ͹ CNFs ΓΕ΍༑Ηͪٷ஥೵Νࣖͪ͢ʤFig. 4ʥɽ  
 









K : Equilibrium constant, qm : Maximum absorption amount of indole 
(A) 1hr㻌
Concentrations of adsorbent (mg/mL)㻌









































































Concentrations of adsorbent (mg/mL)㻌






K (103 L/g) qm (mg/g) 
1 hr 
0.8 ± 0.4 22.5 ± 6.4 
0.7 ± 0.2 23.1 ± 2.9 
0.3 ± 0.1 6.7 ± 1.5 
0.2 ± 0.01 2.3 ± 0.2 
K (103 L/g) qm (mg/g) 
24 hr 
0.8 ± 0.5 23.3 ± 4.6 
7.3 ± 3.0 97.7 ± 21.2 
0.3 ± 0.03 6.2 ± 0.2 
0.2 ± 0.05 2.4 ± 0.2 

Langumuir ͹ٷ஥౵Ի͖ࣞΔฑߩఈ਼ (K) ͕Γ;࠹୉ٷ஥ྖ (qm) Νࢋड़ͪ݃͢Վ (ࣰ
ݩ͹෨ʁ΢ϱχʖϩٷ஥೵඲Ճࢂল)ɼSDACNFs ͹ 24࣎ؔޛͶ͕͜Ζ΢ϱχʖϩ࠹୉ٷ஥ྖ
ͺɼAST-120 ͹ 1/4 ఖౕͲ͍Ζ͗ɼCNFs Ώ DAC Ͷർ΄ͱ 4ʛ10 ഔ୉͘͏͞ͳ͗Κ͖Ζɽ
ΉͪɼSDACNFs ͹ K஍͕Γ; qm ஍ ͺ 1࣎ؔޛͳ 24࣎ؔޛͲรԿ͢͵͏͞ͳ͖Δɼٷ஥





୊ 2ߴ SDACNFs ͹ਝฯޤ͕Γ;߇࢐ԿްՎ 
 
SDACNFs ͶΓΖਝฯޤްՎΝݗ౾ͤΖͪΌɼ5/6ਝଃఢड़ढ़Νࢬߨͪ͢ϧρφͶΓΕݗ
౾ͪ͢ɽ4ुؔ͹༩ඍࣄүޛɼSDACNFsɼDACɼAST-120 ΝͨΗͩΗ 40 mg/kg/day Ͳܨ޳౦
༫͢ɼ0ु͕Γ; 4ुؔޛͶࡀ݄͢ɼ֦ झ඲ՃΝߨͮͪɽ౦༫ 4ुޛͶ͕͜Ζਫ਼ԿָϏϧϟʖ
νͲ͍Ζ೚ો஢ો (blood urea nitrogen, BUN)ɼέϪΠοωϱ (creatinine)ɼໃؽϨϱ (inorganic 
phosphorus, P)ɼIS ೳౕ͹รಊΝ଎ఈͪ݃͢ՎɼSDACNFs ٶ; AST-120 ౦༫܊Ͷ͕͏ͱɼඉ
౦༫܊ͳർֳ͢ͱɾਝ্֒ཊ੏͹ܑ޴͗؏ࡱ͠ΗͪɽಝͶ SDACNFs ౦༫܊Ͳͺɾͤ΄ͱ͹
ਝ্֒ϏϧϟʖνͶ͕͏ͱ༙қ͵ఁԾ͗؏ࡱ͠Ηͪ (Table 2)ɽ࣏Ͷɾ౦༫ 4ुޛͶ͕͜Ζ߇

























Values are expressed as the mean ± SEM (n = 4-6 rats per group). 


















Fig. 5. Effects of SDACNFs, DAC and AST-120 treatments on indices of oxidative stress using plasma 
antioxidant potential (PAO). 
Results are shown for 0 (white) and 4 (black) weeks. Results are expressed as the mean ± SEM (n = 4-
6 rats per group). 
#p < 0.05, compared with CRF rats. 
 
 
Body weight (g)㻌 0 week㻌4 week㻌
339.7 ± 14.4㻌








Serum BUN (mg/dL)㻌 0 week㻌4 week㻌
70.1 ± 5.4 
127.8 ± 22.5 
59.5 ± 6.2㻌










0.9 ± 0.1 
1.9 ± 0.5 
0.7 ± 0.1㻌






Serum P (mg/dL)㻌 0 week㻌4 week㻌
6.7 ± 0.21 
9.9 ± 2.15 
6.0 ± 0.41㻌






Serum IS (μM)㻌 0 week㻌4 week㻌
11.9 ± 1.4 
26.5 ± 4.1 
9.2 ± 1.9㻌






Serum PAO (μM)㻌 0 week㻌4 week㻌
697.1 ± 63.6 
500.6 ± 63.6 
617.4 ± 134㻌
































୊ 3ߴ SDACNFs Ν౦༫ͪ͢ϧρφ͹ਝૌ৭͹؏ࡱ  
 
ࢾݩ֋࢟ 4ुޛ͹ਝଃΝఢड़ޛɼPAS ઝ৯ (Periodic acid Schiff stain)ɼMasson’s trichrome 
ઝ৯ɼ8-OHdG ઝ৯ΝߨͮͪɽPAS ઝ৯ (Fig. 6A) ͺ౸νϱϏέ࣯Νઝ৯ͤΖ๏๑Ͳ͍Εɼ
خఊຜ͗ͺͮ͘Εͳઝ৯͠ΗΖͪΌࢵځରΏ೚ࡋ؇͹รԿΝ؏ࡱͤΖ͹Ͷ༙༽Ͳ͍Ζɽ
Masson’s trichrome ઝ৯ (Fig. 6B) ͺ᡾ݬથңΝઝ৯ͤΖ๏๑Ͳ͍Εɼૌ৭͹તңԿΝ඲Ճͤ
Ζ͞ͳ͗Ͳ͘Ζɽ8-OHdG ઝ৯ (Fig. 6C) ͺ deoxyguanosine (dG) ͗࢐Կ͠Ηͱਫ਼ͣΖ 8-
hydroxy-2’-deoxyguanosine  (8-OHdG) Νઝ৯ͤΖ΍͹Ͳɼ࢐ԿηφϪηϜʖΩʖͳ͢ͱ༽͏































































Fig. 6. Micrograph images for the renal tissue of CRF model rats after administration of SDACNFs. (A) 
Periodic acid–Schiff (PAS) staining, (B) Masson’s trichrome staining, and (C) immunofluorescence 
staining of renal 8-OHdG (8-hydroxy-2b-deoxygenase) images. Non-treated CRF rats and SDACNFs-
treated CRF rats were measured after 4 weeks of administration as described in materials and methods. 












୊ 3ઇ ߡࡱ 
 







ഋड़Ͳ͘ΖՆ೵੓͍͗Ζɽͨ ͞ͲɼSDACNFs ͹΢ϱχʖϩٷ஥೵Ν in vitro Ͳ඲Ճͪ͢ͳ͞
ΘɼψόϓΟ΢ώʖͶմࡇͤΖ઴͹ݬྋͲ͍Ζ DAC ͕Γ;୦ΠιοϩԿౕ͗ 1%ఖౕͳఁ
͏ CNFs ͳർֳ͢ͱ༑Ηͪ΢ϱχʖϩٷ஥ްՎΝࣖͪ͢ɽްིద͵΢ϱχʖϩ͹ٷ஥Ͷͺɼ
ψόϓΟ΢ώʖԿͶΓΖන໚੷͹ଁ୉ͳΠϝόخ͹ଚࡑ͗॑གྷͲ͍Ζ͞ͳ͗ࣖ͠Ηͪ (Fig. 4 
and Table 1)ɽ࣏Ͷɼ5/6ਝଃఢड़ढ़Νࢬߨͪ͢ CRF ϧρφͶ SDACNFs Νຘೖܨ޳౦༫ͤΖ
͞ͳͶΓΖਝฯޤްՎΝݗ౾ͪ͢ɽͨ ͹݃ՎɼSDACNFs ͺ DAC ͕Γ; AST-120 ΓΕ΍έ
ϪΠοωϱΝͺͣΌͳ֦ͪ͢झ݄ੜϏϧϟʖνրવްՎΝࣖͪ͢ (Table 2)ɽIn vitro Ͷ͕͜Ζ
SDACNFs ͹΢ϱχʖϩٷ஥ྖͺ AST-120ΓΕ΍ఁ͏Ͷ΍ؖΚΔͥ ɼ in vivo Ͳͺ AST-120 
ΓΕ΍߶͏ਝฯޤްՎΝࣖͪ͢ɽ͞ Ηͺɼ΢ϱχʖϩ͹ٷ஥Ґ֐͹ްՎ͍͗Ζͳߡ͓ΔΗΖɽ
Ϋοϱ͕Γ;ΫφγϱͺɼভԿ؇಼Ͷ͕͏ͱ೚ಡ঳෼࣯ͫ͜Ͳ͵͚ɼਫ਼ର಼࢐Կଇ਒෼࣯Ͳ
͍ΖఁືౕϨϛνϱϏέ࣯ (Low-density lipoprotein, LDL) ͵ʹ͹ࢹ࣯੔෾Νٷ஥ʀഋड़͢ɼ߇
࢐ԿްՎΝࣖͤ͞ͳΝๅࠄͪ͢ 7,10,11)ɽSDACNFs Ͷ΍ࢹ࣯Νٷ஥ʀഋᔖͤΖްՎ͗ๅࠄ͠Η
ͱ͏Ζ 31) ͞ͳ͖Δɼಋ༹͹ϟΩωθϞͲ߇࢐ԿްՎΝࣖͪ͢΍͹ͳߡ͓ΔΗΖɽࣆࣰɼਫ਼ର
಼߇࢐Կ೵Νࣖͤ PAO ͺ SDACNFs ౦༫܊Ͷ͕͏ͱଁՅ͢ (Fig. 5)ɼΉͪɼ8-OHdG ઝ৯͹
































Fig. 7. Strategy to control renal failure progression. 
Mild㻌 Severe㻌Progression of disease㻌
Severe㻌Mild㻌 Increased oxidative stress㻌






Uremia㻌 Chronic anemia㻌Cardiovascular disease㻌
Kidney transplantation㻌
 Administration㻌
 of Kremezin® 㻌
Prevention and treatment with functional foods㻌
SDACNFs㻌






1) ೚ಡ঳෼࣯ IS ͹઴ۨ෼࣯Ͳ͍Ζ΢ϱχʖϩ͹ٷ஥೵Ν in vitro Ͳ඲Ճͪ͢ͳ͞Θɼ
SDACNFs͹ٷ஥೵ͺɼψόϓΟ΢ώʖԿ͢ͱ͏͵͏ DAC ͕Γ;୦ΠιοϩԿౕ͹ఁ
͏ CNFs ΓΕ΍߶͏͞ͳ͗ࣖ͠Ηͪɽ 
 
2) SDACNFs ͺɼCRF ͶΓΕର಼Ͷட੷ͤΖ BUNɼέϪΠοωϱɼໃؽϨϱɼISɼPAO 
Νրવ͢ɼ͞͹ްՎͺྡজͲ࢘༽͠Ηͱ͏Ζ AST-120 (έϪϟζϱ®) ΓΕ߶͖ͮͪɽ 
 



















୊ 3হ SDACNFs ηϛϱζ͹૓উ࣑ྏͶؖͤΖݗ౾ 
  










ΚΗΖʰ ड़ ʀ݄Ԏ঳غ ɼʱતңլࡋ๖͹༣ૺଁ৫͕Γ;݄؇৿ਫ਼ʀ೓լܙ੔ً͗͞Ζʰ ଁ৫غ ɼʱ













ͪ͢૓উඅ෶ࡒ (ϗηΫοϱ®) ͗֋൅͠Ηɼҫྏݳ৖Ͳ΍࢘༽͠Ηͱ͏Ζɽ 
  ຌݗ౾Ͳͺɼ͞ΗΉͲͶ૓উ࣑༌ଇ਒ްՎ͗ๅࠄ͠Ηͱ͏ΖΫοϱ͕Γ;ΫφγϱΝψ
όϓΟ΢ώʖԿͪ͢ SDACNFs Νηϛϱζয়ͶՅ޽ͤΖ͞ͳͲɼ͠Δ͵Ζ૓উ࣑༌ଇ਒ްՎ
ਜ਼৙ൿේ ड़݄ʀԎ঳غ ଁ৫غ ࠸ߑ஛غʀ࣑༌

͗غଶͲ͘Ζͳߡ͓ɼηϛϱζ͹ in vitro ٷਭಝ੓Ν඲Ճ͢ɼin vivo Ͷͱϧρφ૓উϠυϩ
Ͷ͕͜Ζ૓উ࣑༌ଇ਒ްՎΝ඲Ճͪ͢ɽ 
 
୊ 2ઇ SDACNFs ηϛϱζ͹༙༽੓඲Ճ 
 
୊ 1ߴ SDACNFs ηϛϱζ͹௒੣ͳන໚؏ࡱ 
 
  SDACNFs ηϛϱζ͹௒੣ͺɼௗ๏ܙ͹ܗͶ SDACNFs 3.5 g Ν೘Ηɼ౜݃ף૫ͤΖ͞
ͳͲ௒੣ͪ͢ (Fig. 9)ɽ͞͹ηϛϱζΝૺࠬܗుࢢݨඏں (SEM) Ͳ؏ࡱͪ͢ͳ͞Θɼψόϓ
Ο΢ώʖતң͗෵ࡸͶཙΊ߻ͮͪື͵ηϛϱζয়ߑଆΝ͢ͱ͏Ζ͞ͳ͗ࣖ͠Ηͪɽ͞ΗͶଲ
͢ɼࢤ൤͹૓উඅ෶ࡒͲ͍ΖϗηΫοϱ®ͺɼଢ͏તң͗ཙΊ͍ͮͪ૊͏ηϛϱζয়ߑଆΝ͢





















Fig. 10. SEM images of surface of SDACNFs sponge and Beschitin®. 













ՃͤΖ΍͹Ͳ͍Ζɽͨ͹݃ՎɼSDACNFs ηϛϱζ͹ંৰֱͺ 10භؔ͹ؔͶ 86.4 o͖Δ 49.6 
oͶรԿ͢ɼඉ৙ͶೠΗΏͤ͏੓࣯Ν࣍ͯ͞ͳ͗ࣖ͠Ηͪ (Fig. 11)ɽ͞ΗͶଲ͢ͱɼϗηΫο
ϱ®ͺɼ઎Άʹ͹ SEM ժ଀ (Fig. 10) ͖Δ΍Κ͖ΖΓ͑Ͷતң͗ඉ৙Ͷଢ͚ɼ伳ؔ͹ଡ͏૊
͏ηϛϱζͲ͍ͮͪͪΌɼන໚͗ೠΗΖͳ͏͑ΓΕ΍伳ؔΝਭథ͗௪գͤΖয়ସͶ͵Εɼં











































  ࣏ͶɼSDACNFs ηϛϱζ͕Γ;ϗηΫοϱ®͹ٷਭྖΝ଎ఈͪ͢ɽͨ͹݃ՎɼSDACNFs 
ηϛϱζ͹ٷਭྖͺٷਭ઴ͳർֳ͢ͱ༁ 55ഔଁ୉͢ (Fig. 12 A)ɼٷਭޛ΍ηϛϱζ͹ܙয়Ν











































































୊ 3ߴ SDACNFs ηϛϱζ͹૓উ࣑ྏްՎ 
 
  ઴ߴͲɼSDACNFs ηϛϱζͺ૓উ໚͹ਭ෾Νٷफʀฯ࣍ͤΖ͞ͳͲɼ૓উ໚Νॉ෾͵࣬
७؂ڧͶͲ͘ΖՆ೵੓Νࣖͪ͢ɽͨ ͞Ͳɼ૓উϠυϩϧρφΝ༽͏ͱɼSDACNFs ηϛϱζ͹
૓উ࣑༌ଇ਒ްՎͶͯ͏ͱݗ౾ͪ͢ɽ 

















Fig. 13. Schematic study design of the excision wound model. The experimental procedures for the 
excision wound model are shown in a box. 
 
  Fig. 14 A Ͷ૓উ໚੷͹รԿΝࣖͤɽ૓উ໚ͺ࣎ؔܨգͳͳ΍Ͷͨ͹बΕ͖Δൿේ͗࠸ਫ਼
͢ɼ૓উ໚੷ͺक़ঘͪ͢ɽSDACNFs ηϛϱζͺɼາ࣑ྏ͕Γ;ϗηΫοϱ®ͳർֳ͢ͱɼ̐
ೖ໪ΓΕ૓উ໚͹क़ঘ͗؏ࡱ͠Ηɼͨ͹ޛ΍༑Ηͪ૓উ໚੷क़ঘްՎ͗؏ࡱ͠Ηͪɽ 
  ࣏Ͷ Fig. 14 BͶ 14ೖ໪Ͷ͕͜Ζൿේ͹ HE ઝ৯͹݃ՎΝࣖͤɽາ࣑ྏ͕Γ;ϗηΫο




Measure wound area 
HE staining 
Change samples and measure wound area 
Operation Apply samples Fixation 
0 2 4 6 8 10 12 14 






























Fig. 14. Effects of SDACNFs sponge and Beschitin® on wound areas in the excision wound model. Data 
are presented as the mean ± S.D. n = 7–8 in each group. Each letter indicates a significant difference as 
follows; a: p < 0.01 compare with the untreated group, b: p < 0.05 compared with the untreated group, 
c: p < 0.01 compared with the Beschitin® group, d: p < 0.05 compared with the Beschitin® group (A). 
Histopathological assessment of the effects of SDACNFs sponge and Beschitin® (B). 

































୊ 3ઇ ߡࡱ 
 
  SDACNFs Ν౜݃ף૫͢ͱ௒੣ͪ͢ SDACNFs ηϛϱζͺɼψόϓΟ΢ώʖ͗ືͶཙΊ
߻ͮͪߑଆΝ͢ͱ͕Ε (Fig. 10)ɼͨ ͹ٷਭ੓ͺࢤ൤͹૓উඅ෶ࡒͲ͍ΖϗηΫοϱ®ΓΕ΍༁
3ഔ߶͖ͮͪ (Fig. 12)ɽ͞ ΗͺɼψόϓΟ΢ώʖԿͶΓΕηϛϱζߑଆ͗ືͶ͵Εɼਭ෾Νฯ
࣍͢Ώ͚ͤ͵ͮͪ͞ͳͶًҾͤΖ΍͹ͳߡ͓ΔΗΖɽ͞͹ SDACNFs ηϛϱζΝϧρφഐ෨
ൿේΝঈڊͪ͢૓উϠυϩϧρφͶన༽ͪ݃͢ՎɼϗηΫοϱ®ΓΕ΍༑Ηͪ૓উ໚੷क़ঘް
ՎΝࣖͪ͢ (Fig. 14 A)ɽ͠ ΔͶɼൿේૌ৭͹ HE ઝ৯Ͷ͕͏ͱ΍ൿේ͹࠸৏ൿԿ͗؏ࡱ͠Ηɼ
SDACNFs ηϛϱζͺ༑Ηͪ૓উൿේଇ਒ްՎΝࣖͪ͢ (Fig. 14 B)ɽ 
  ౜݃ף૫͢ͱ͏͵͏ SDACNFs ͶΓΖ૓উ࣑༌ଇ਒ްՎͺɼͤͲͶ Izumi Δ͗ๅࠄ 4) 






ͱ͏͵͏ɽψόϓΟ΢ώʖԿ͢ͱ͏͵͏ΫοϱΏΫφγϱ͹ްՎͳ͢ͱɼMinami Δ 16,52) ͺɼ
૓উ࣑༌գఖ͹࠹ॵ͹ஊ֌Ͳ͍Ζʰड़݄ʀԎ঳غʱͶଲͤΖɼ߇ ݄ӹڿݽ׈੓ 53)ɼ߈ ߇ۗ












































1) SDACNFs Ν౜݃ף૫ͤΖ͞ͳͲɼ؈สͶ SDACNFs ηϛϱζ͗௒੣Ն೵Ͳ͍ͮͪɽ 
 



























୊ 4 হ ϕϪχωμϫϱ (PD) ؜༙ SDACNFs/ηϩϙϔοϩΦʖτϩ-β-εέϫυΫηφϨϱ 
(SBE-β-CyD) ΰϩ (PD؜༙ΰϩ) ͹ DSS ༢൅௷ ੓୉ௐԎ࣑ྏͶؖͤΖݗ౾ 
  
୊ 1ઇ ঄ 
 
௷ ੓୉ௐԎͺɼݬҾ෈໎͹ອ੓࠸೫੓ভԿ؇Ԏ঳࣮׳Ͳ͍Εɼࠅ͹ೋබࢨఈΝण͜ͱ
͏Ζɽը͗ࠅͶ͕͜Ζ׳ं਼ͺ༁ 14ຬਕ (޲ਫ਼࿓ಉ঴௒΄ɼ2012೧) Ͷୣ͢ͱ͏ΖɽҲൢͶɼ
බรͺ௜ௐ͖ΔͺͣΉΕ࿊କదͶ޳ଈͶ਒ఴ͢ͱ͏͚͞ͳ͗எΔΗͱ͕Εɼබร͹෨ҒͶΓ
Εɼસ୉ௐԎܗɼࠪଈ୉ௐԎܗɼ௜ௐԎܗͶ෾ྪ͠ΗΖɽͨ͹ׄ߻ͺɼસ୉ௐԎܗ 3 ׄɼࠪ
ଈ୉ௐԎܗ 4ׄɼ௜ௐԎܗ 3ׄͳ͏ΚΗͱ͕Εɼ஋ঃർͺ͕Γͨ 1ଲ 1Ͳɼ൅঳೧ྺͺ 20͖
Δ 24ࡂͶϒʖέ͍͗Ζ 67)ɽݳࡑɼ࣑ྏ༂ͳ͢ͱɼ5-ΠϝόγϨοϩ࢐ɼγϧμηϩϓΟϒϨ
ζϱɼϕϪχωμϫϱ (PD)ɼεέϫηϛϨϱɼνέϫϨϞηɼ΢ϱϓϨΫεϜϔ͵ʹ͹Ԏ঳
Νཊ੏ͤΖ༂ࡐ͗࢘༽͠Ηͱ͏Ζ 68)ɽͨ ͹஦Ͳ΍ PD ͺɼܲ ঳͖Δ॑঳͹঳ྭͶଲ͢ɼௐ஭ɼ
ܨ޳ɼ੫஭Ͳ෱߁͚࢘༽͠ΗΖ༂ࡐͲ͍Ζ͗ɼௗغͶΚͪΖ࿊ೖ୉ྖ౦༫͗ߨΚΗΖͪΌɼ
ͨ͹෯ࡠ༽Ͳ͍Ζ༢൅״ઝ঳ɼକ൅੓෯ਝൿ࣯ؽ೵෈સɼ౸೚බɼέρεϱή঳ޫ܊༹঳য়
͵ʹ͗໲ୌͳ͵ΖɽPD ͶΓΖ࣑ྏްՎΝ޴৏ͦ͠ΖͪΌͶͺɼೋਭ༻੓༂෼Ͳ͍Ζ PD ͹
ਭ༻੓Νրવ͢ɼްིదͶٷफͦ͠ͱ૱౦༫ྖΝݰΔ͢ɼ౦༫ֶؔΝԈௗͤΖ͞ͳ͗॑གྷͲ
͍Ζ͗ɼͨ͹Γ͑͵੣ࡐָద޽෋͗͵͠Ηͪ੣ࡐͺݡ౲ͪΔ͵͏ɽͨ ͞ͲɼஸंͺɼPD ͹ਭ
༻੓ΝրવͤΖͪΌͶ༂෼༻մࡠ༽Ώ༂෼҈ఈԿࡠ༽͵ʹΝ༙ͤΖ CyD 33,34) Ͷ஥໪͢ɼͨ
͹஦Ͳ΍ΠωΨϱ੓Ͳ͍Εɼ஭ࣻࡐ͹శՅࡐͳ͢ͱ΍࢘༽ࣰ੹͹͍Ζ҈સ੓͹߶͏ CyD ༢
಍ରͲ͍Ζ SBE-β-CyD (Fig. 15) 69) ΝΩοΨϱ੓ SDACNFs ͹෵߻ରԿࡐͳ͢ͱ༽͏ͱ߶ک
ౕ͹ΰϩΝ௒੣ͪ͢ 35)ɽͨ͹ΰϩͶ PD Ν෩೘ͪ͢ PD ؜༙ SDACNFs/SBE-β-CyD ΰϩ 











6 7 8 
2.4 6.6 4.9 
1352 2179 2071 
D.S. : Degree of substitution, Mw : Molecular weight 















Fig. 15. Structure of sulfobutyl ether-cyclodextrins.  
 
୊ 2ઇ SDACNFs/SBE-β-CyD ΰϩ͹௒੣ 
 
୊ 1ߴ SDACNFs/֦झ CyD ΰϩ͹௒੣ 
 







Fig. 16. Preparation of SDACNFs/cyclodextrins gel. 
 
֦झ CyDs Ν༽͏ͱΰϩܙ੔೵Ν඲Ճͪ݃͢Վɼෝు՛Ν࣍ͪ͵͏ α-CyDɼβ-CyDɼγ-
CyDɼϐχϫΫεϕϫϒϩ-β-CyD (HP-β-CyD)ɼϐχϫΫεϔοϩ-β-CyD (HB-β-CyD) ͕Γ;
ζϟοϩ-β-CyD (DM-β-CyD) ͲͺΰϩԿً͗͞Δ͵͖ͮͪɽҲ๏ɼෝు՛Ν࣍ͯ SBE-β-CyD 
ͲͺΰϩԿً͗͞Ζ͞ͳ͖ΔɼSDACNFs ͹ΰϩԿͶͺෝు՛Ν࣍ͯׯ೵خ͗චགྷͲ͍Ζ͞
ͳ͗ࣖ͠Ηͪɽ͠ΔͶɼψόϓΟ΢ώʖԿ͢ͱ͏͵͏ DAC ͲͺΰϩԿً͗͞Δ͵͖ͮͪ͞
SDACNFs 1 g 
֦ 10% CyDs ༻ӹ 
1 mL 24 hr 
ΰϩԿ ʕ ΰϩԿ ʹ 





















Fig. 17. Appearance of SDACNFs/cyclodextirns gel. 
 
 
୊ 2ߴ SDACNFs/SBE-CyD ΰϩ͹෼੓඲Ճ 
 
  ΰϩԿً͗ͮͪ͞ SBE-β-CyD Ͷ஥໪͢ͱɼ SBE-α-CyD (SBEخ͹஖׷ౕʁ2.4)ɼSBE-β-
CyD (SBEخ͹஖׷ౕʁ6.6)ɼSBE-γ-CyD (SBEخ͹஖׷ౕʁ4.9) Ν༽͏ͱಋ༹͹๏๑Ͳ CyDs
ೳౕΝรԿͦ͠ΰϩΝ௒੣͢ɼΰϩکౕΝϪΨϟʖνʖͲ඲Ճͪ͢ɽCyDsೳౕΝ 1 %Ͷݽఈ
͢ͱ௒੣ͪ͢ΰϩ͹೬ౕͺɼ֦ CyDs͹࣍ͯෝు՛ (Fig. 15) Ͷғଚ͢ͱɼSBE-α-CyD < SBE-
γ-CyD < SBE-β-CyD ͹ॳͶ߶͏஍Νࣖͪ͢ (Fig. 18 A)ɽ͠ΔͶɼ1 %ɼ5 %͕Γ; 10 %͹ೳౕ
Ͳ௒੣֦ͪ͢ΰϩ͹ͦΞஇଐౕ 1 s-1Ͷ͕͜ΖͦΞஇ೬ౕΝ CyD ೳౕͶଲ͢ͱϕϫρφͪ͢
݃ՎɼSBE خ͹஖׷ౕ͹࠹΍߶͏ SBE-β-CyD ͺఁೳౕͲ೬ౕ͗࠹୉ͳ͵ͮͪ (Fig. 18 B)ɽ
ͨ͞ͲɼҐ߳͹ݗ౾Ν SBE-β-CyD Ν༽͏ͱߨͮͪɽ 
SDACNFs with water 
DAC with water 
SDACNFs with α-CyD 
SDACNFs with β-CyD 
SDACNFs with γ-CyD 
SDACNFs with HP-β-CyD 
SDACNFs with HB-β-CyD 
SDACNFs with DM-β-CyD 


























Fig. 18. Plots for the shear viscosity versus shear rate of SDACNFs/1 % SBE-CyDs gels (A). Effect of 
SBE-CyDs concentration on the shear viscosity of gels (B). 
SDACNFs alone (white square), SDACNFs/SBE-α-CyD gel (white circle), SDACNFs/SBE-β-CyD gel 
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୊ 3ઇ PD ؜༙ SDACNFs/SBE-β-CyD ΰϩ͹༙༽੓඲Ճ 
 
୊ 1ߴ PD ؜༙ΰϩ͹௒੣ͳΰϩ͹کౕ͕Γ;ΰϩ͖Δ͹ PD ͹๎ड़඲Ճ 
 
SDANCFs/SBE-β-CyD ΰϩ΃͹ PD ෩೘ͺɼSDANCFs Ͷ PD/SBE-β-CyD ༻ӹΝਃ௰ͤ
Ζ͞ͳͲߨͮͪɽPD ؜༙ SDACNFs/SBE-β-CyD ΰϩ (PD ؜༙ΰϩ) ͹کౕͺ PD ෩೘઴
ޛͲรԿ͢͵͖ͮͪ (Fig. 19)ɽ 
࣏ͶɼPD ؜༙ΰϩ͖Δ͹ PD ๎ड़Νೖຌ༂ۃ๏୊ 1ӹ (pH1.2ɼҥӹϠυϩ) ͕Γ;୊
2ӹ (pH6.8ɼௐӹϠυϩ) Ͳ඲Ճͪ͢ͳ͞Θɼ୊ 1ӹ͕Γ;୊ 2ӹͳ΍Ͷ PD/SBE-β-CyD ༻
ӹͳർֳ͢ͱঅ๎੓Νࣖ͢ɼ͠ΔͶɼ௒੣Ͷ༽͏ͪ SBE-β-CyD ೳౕғଚదͶ PD ͹෩೘ྖ
͗ଁ୉ͪ͢ (Fig.20)ɽͨ͹࣎͹๎ड़ؽߑΝմੵͪ݃͢Վ (ࣰݩ͹෨ʁ༻ड़ࢾݩࢂল)ɼ0࣏๎ड़
ΓΕ΍ Higuchi ࣞͶϓΡρφͤΖ͞ͳ͖Δΰϩ͖Δ͹ PD ๎ड़ͺϜφϨέηܗ͹๎ड़Νࣖ





























































Fig. 20. Release profiles of PD/SBE-β-CyD solution (white triangles, PD content about 2.8 mg), 
PD/SDACNFs/SBE-β-CyD gel at SBE-CyD concentration of 1 (white circle, PD content about 0.62 
mg), 5 (gray circle, PD content about 2.3 mg) and 10 % (black circle, PD content about 2.8 mg) in JP 1st 
fluid (A) and 2nd fluid (B) at 37 oC, measured by rotating basket method (50 rpm). 
Each point represents the mean ± S.E. of 3-6 experiments. 
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SDACNFs/SBE-β-CyD (1 %) 
SDACNFs/SBE-β-CyD (5 %) 
SDACNFs/SBE-β-CyD (10 %) 
Zero order Higuchi 
r2 K0 (hr-1) r2 K0 (hr-0.5) 
6.8 
SDACNFs/SBE-β-CyD (1 %) 
SDACNFs/SBE-β-CyD (5 %) 
SDACNFs/SBE-β-CyD (10 %) 
0.714 28.6 0.992 42.0 
0.633 30.4 0.984 45.1 
0.682 31.2 0.990 46.1 
0.727 28.7 0.994 42.1 
0.735 29.8 0.991 43.7 
0.616 31.9 0.980 47.4 

୊ 2ߴ PD ؜༙ΰϩ͹ PD ର಼ಊସͳভԿ؇಼଼ཻ੓඲Ճ 
 
 PD ؜༙ΰϩΝϧρφͶܨ޳౦༫ͪ݃͢ՎɼPD/SBE-β-CyD ༻ӹͳർֳ͢ͱɼTmax ͺ༁ 2
ഔͶԈௗɼAUC ͺ༁ 3 ഔͶଁ୉ɼMRT ͺ༁ 3 ഔͶԈௗɼBA ͺ༁ 4 ഔͶଁ୉ͪ͢ (Fig. 21 













Fig. 21. Mean plasma pharmacokinetic profile of PD only (gray circle), PD/SBE-β-CyD solution (white 
circle), PD/SDACNFs mixture (white triangle) and PD/SDACNFs/SBE-β-CyD gel (black circle) in rats 
following an oral administration (8 mg/kg). 









Table 4. Mean plasma pharmacokinetic profile for prednisolone in rats following an oral administration 
(8 mg/kg). 
Each point represents the mean ± S.E. of 3 experiments. 
ap < 0.01 for PD suspension, bp < 0.05 for PD suspension, cp < 0.01 for PD/SBE-β-CyD solution, dp < 
0.05 for PD/SBE-β-CyD solution, ep < 0.01 for PD/SDACNFs mixture, fp < 0.05 for PD/SDACNFs 
mixture. 























































͞͹ PD ର಼ಊସ͹րવͺɼSDACNFs ͹ΰϩԿͶΓΖ PD ͹অ๎ԿͶՅ͓ɼভԿ؇಼଼ཻ
੓ͶًҾͤΖͳߡ͓ΔΗΖͪΌɼ࣏Ͷ PD ͹େΚΕͶ MRI ଆӪࡐͲ͍Ζ Gd-DTPA ؜༙
SDACNFs/SBE-β-CyD ΰϩ (Gd-DTPA ؜༙ΰϩ) Ν௒੣͢ɼভԿ؇಼଼ཻ੓Ν MRI ͶΓΕ
඲Ճͪ͢ɽFig. 22͹പ͚ҕͮͪ෨෾͗ҥ͖Δঘௐ΃କ͚ভԿ؇ͳߡ͓ΔΗΖɽGd-DTPA ୱಢ

















Fig. 22. MRI images of mice on 30 and 60 min after oral administration of either an aqueous solution 
of Gd-DTPA or Gd-DTPA/SDACNFs/SBE-β-CyD gel. 





ʖ؜༙ SDACNFs/SBE-β-CyD ΰϩ (Φώϱηϔϩʖ؜༙ΰϩ) Ͳͺɼ౦༫ޛ 60෾ͲͺҥͶଚ
ࡑ͢ɼ240෾ޛͲ΍ঘௐԾ෨Ͷଚࡑ͢ͱ͏Ζ͞ͳ͗؏ࡱ͠Ηͪɽ 
Ґ৏͹݃ՎΓΕɼPD ؜༙ΰϩͺɼSDACNFs ͹ΰϩԿͶΓΖ PD ͹অ๎ԿͶՅ͓ɼভԿ
؇಼଼ཻ੓͗޴৏ͪ͢͞ͳͶًҾͤΖ͞ͳ͗໎Δ͖ͳ͵ͮͪɽ 
Gd-DTPA Gd-DTPA/SDACNFs/SBE-β-CyD gel 



















Fig. 23. Appearanece of the digestive tract after oral administration of either an aqueous solution of 


























Evans blue solution 
Evans blue/SDACNFs/SBE-β-CyD gel 
30 min 60 min 120 min 
60 min 120 min 240 min 

୊ 4ઇ PD ؜༙ΰϩ͹ DSS ༢൅௷ ੓୉ௐԎ࣑ྏްՎ 
 
୊ 1ߴ DAI ηαΠͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճ 
 
  ௷ ੓୉ௐԎϠυϩ͹ࡠ੔Ͷͺɼਥ࢐ 70)ɼφϨωφϫϗϱκϱηϩϙϱ࢐ (TNBS) 71) ͕























Fig. 24. Scheme of the study design of the DSS induced colitis model and DAI score. 
 
බସ͹॑঳ౕ඲Ճͺ Disease activity index score (DAI ηαΠ) 73,74) Ν༽͏ͱߨͮͪ (Fig. 
24)ɽDAI ηαΠͺɼର॑͹ݰঙɼೊสɼ݄ส͹ 3ߴ໪͹ηαΠ͹߻ܯͲ඲Ճ͠ΗΖɽDSS Ͷ
ΓΕ௷ ੓୉ௐԎΝ༢൅͠ΗͪϜΤηͺɼࢾݩ֋࢟ 2ʛ3 ೖͲೊสΏ݄ส͹ܑ޴͗؏ࡱ͠Η
Day 
0 3 5 7 8 
Mice were administered 3 % DSS and libitum for test period 
Record of DAI score 
: Measure the bowel, spleen weight and blood cell counts 
: Oral administration of samples 
Disease activity index (DAI) 

















ͪɽͨ͞Ͳɼ3໪ΓΕ 2ೖֶؔͲɼPD ݔ୛ӹɼPD/SBE-β-CyD ༻ӹɼPD/SDACNFs ࠠ߻෼ɼ
PD ؜༙ΰϩΝܨ޳౦༫ͪ݃͢ՎɼPD ؜༙ΰϩҐ֐͹౦༫܊Ͳͺɼ࣎ؔܨգͳͳ΍Ͷ୉ௐԎ
͹঳য়͗ѳԿ͢ DAI ηαΠ͗৏ত͢ͱ͏ΖͶଲ͢ͱɼPD ؜༙ΰϩͺηαΠ͹৏তΝཊ੏͢













Fig. 25. Effects of PD samples clinical disease activity in DSS-induced colitis, assessed by DAI score. 
ap < 0.05 for 3 % DSS. 
 
୊ 2ߴ ୉ௐૌ৭͕Γ;୉ௐ MPO ׈੓ͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճ 
 
  DAI ηαΠͶΓΕ୉ௐԎ࣑ྏްՎ͗؏ࡱ͠Ηͪ 8 ೖ໪ͶϜΤηΝṌࡶ͢ɼ୉ௐ͹җक़ɼ
୉ௐ MPO (ϝΦϫϘϩΨΫεξʖκ) ׈੓ɼ୉ௐૌ৭͹ HE ઝ৯Νߨͮͪ (Figs. 26-27)ɽͨ
͹݃ՎɼDSS ͶΓΕ༢൅͠ΗͪԎ঳ͶΓΕɼPD ؜༙ΰϩҐ֐͹౦༫܊Ͳͺ୉ௐ͗җक़͢ͱ
͏Ζ͹Ͷଲ͢ͱɼPD ؜༙ΰϩͲͺ୉ௐ͹җक़Νཊ੏ͪ͢ɽ͞ ͹݃ՎΝൕӫ͢ͱɼԎ঳ϜʖΩ















































Fig. 26. Effects of PD samples clinical disease activity in DSS-induced colitis, assessed by colon length 


















Fig. 27. Histopathological changes on day 8 in DSS-induced colitis.  




































3 % DSS PD suspension PD/SBE-β-CyD solution 





















୊ 3ߴ ݄ځ੔෾͕Γ;ᡰଃ॑ྖͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏ͹඲Ճ 
 
௷ ੓୉ௐԎ͗ѳԿͪ͢৖߻ɼ୉ௐԎͶΓΖड़݄ΏԎ঳Ͷ൒͏รԿͤΖ݄ځϏϧϟʖν
Ͷͯ͏ͱ඲Ճͪ͢ (Table 5)ɽPD ؜༙ΰϩҐ֐͹౦༫܊Ͳͺɼ୉ௐ͹Ԏ঳ͶΓΕപ݄ځ਼ 
(WBC) ͺ৏তɼड़݄ͶΓΕ੼݄ځ਼ (RBC) ͕Γ;ϖϠήϫϑϱ (Hb) ͺఁԾɼΉͪɼ݄ঘ
൚਼ (PLT) ͺ৏তͪ͢ɽҲ๏ɼPD ؜༙ΰϩ౦༫܊Ͳͺ͞ΗΔ͹ѳԿΝཊ੏ͪ͢ɽ͠ΔͶɼ
௷ ੓୉ௐԎͲͺɼFig. 26Ͳ؏ࡱ͠Ηͪ୉ௐ MPO ׈੓͹ଁ୉ͶًҾͪ͢࢐ԿηφϪηͶΓ












Table 5. Effects of PD samples clinical disease activity in DSS-induced colitis, assessed by white blood 
cell (WSC), red blood cell (RBC), Hemoglobin (Hb), plate (PLT). 
ap < 0.01 for 3 % DSS, bp < 0.05 for 3 % DSS, cp < 0.01 for PD suspension, dp < 0.05 for PD suspension, 
ep < 0.01 for PD/SBE-β-CyD solution, fp < 0.05 for PD/SBE-β-CyD solution, gp < 0.01 for PD/SDACNF 
mixture, hp < 0.05 for PD/SDACNF mixture. 
 
DSS ͶΓΕӀً͘͞͠ΗΖԎ঳ͶΓΕ඄୉ͤΖᡰଃ 74) ͹඲ՃΝߨͮͪ (Table 6)ɽPD 
؜༙ΰϩҐ֐͹౦༫܊Ͳͺɼᡰଃ͹඄୉Νॉ෾Ͷཊ੏Ͳ͘ͱ͏͵͏͹Ͷଲ͢ͱɼPD ؜༙ΰϩ
Ͳͺ݊৙܊ͳಋ౵͹ϪϗϩΉͲᡰଃ͹඄୉Νཊ੏ͪ͢ɽΉͪɼ݊৙܊ΓΕ΍ᡰଃ͗ঘ͚͠͵














Table 6. Effects of PD samples clinical disease activity in DSS-induced colitis, assessed by spleen 
weight/body weight. 
ap < 0.01 for 3 % DSS, bp < 0.05 for 3 % DSS. 
 










ࡠ༽Ώ༂෼҈ఈԿࡠ༽Ν༙ͤΖ CyD ͹஦Ͳ΍ΠωΨϱ੓Ͳ͍Ζ SBE-β-CyD Ͷ஥໪ͪ͢ɽ
ࣆࣰɼෝు՛Ν࣍ͯ SBE-β-CyD ͺɼਭ࢐ԿψφϨΤϞͳಋ༹Ͷΰϩܙ੔͗Ն೵Ͳ͍ͮͪ 
(Figs. 16-17)ɽ 
  SBE-β-CyD ͺɼ஭ࣻࡐ͹శՅࡐͳ͢ͱྡজͲ͹࢘༽ࣰ੹͍͗ΖͪΌ҈સ੓͗߶͏ɽ͠Δ
ͶɼCyD Ͷ༟པͪ͢ೋਭ༻੓༂෼༻մࡠ༽͵ʹ͹ؽ೵ͳΠωΨϱ੓Ͳ͍Ζ͞ͳΝཤ༽͢ͱɼ
ݜڂஊ֌Ͳͺ͍Ζ΍͹͹Ϋφγϱͳ SBE-β-CyD ΝૌΊΚͦͪঅ๎৥ 75) ΏψόཽࢢԿ 76–78) 















  ࣏ͶɼCyD ͹࣍ͯೋਭ༻੓༂෼༻մࡠ༽Νཤ༽͢ͱɼPD Ν෩೘ͪ͢ PD ؜༙ΰϩΝ௒
੣ͪ͢ɽPD ؜༙ΰϩͳ PDඉ؜༙ΰϩ͹کౕΝർֳͪ݃͢ՎɼPD ͹༙ໃͲΰϩکౕͺรԿ
͢͵͖ͮͪ (Fig. 19)ɽ͞͹͞ͳͺ CyD Ͷใંয়ସͲଚࡑ͢ͱ͏Ζ PD ͗ SDACNFs ͳ 
SBE-β-CyD ͹૮ޕࡠ༽Ν૏֒͢ͱ͏͵͞ͳΝࣖ͢ͱ͏Ζɽೖຌ༂ۃ๏୊ 1ӹ͕Γ;୊ 2ӹͶ
͕͜Ζΰϩ͖Δ͹ PD ๎ड़ͺɼPD/SBE-β-CyD ༻ӹͳർֳ͢ͱঅ๎੓Νࣖ͢ɼͨ͹๎ड़ؽߑ
ͺ Higuchi ࣞ 79) ͶॊͮͪϜφϨέηܗ๎ड़Ͳ͍ͮͪ (Fig. 20 and Table 3)ɽPD ؜༙ΰϩΝ
ϧρφ΃ܨ޳౦༫͢ɼPD ͹ର಼ಊସΝ඲Ճͪ͢ͳ͞ΘɼPD/SBE-β-CyD ༻ӹͳർֳ͢ͱ 
AUCɼMRT ͕Γ; BA ͹ଁ୉͗؏ࡱ͠Ηͪ (Fig. 21 and Table 4)ɽ͞ Ηͺɼΰϩ͖Δ͹ PD ͹
অ๎੓ͶՅ͓ɼΰϩԿͶΓΖভԿ؇಼଼ཻ੓޴৏ͶًҾͤΖ͞ͳ͗ MRI ͕Γ;Φώϱηϔ
ϩʖࣰݩΓΕ໎Δ͖ͳ͵ͮͪ (Figs. 22-23)ɽࣆࣰɼΫφγϱͶͺ೬ຜ෉஥੓ 80) ͍͗ΖͪΌɼ
ψόϓΟ΢ώʖԿͶΓΖ෾ࢆ੓͹޴৏ͳන໚੷͹ଁ୉ɼ͠ΔͶͺΰϩԿͶΓΕভԿ؇಼଼ཻ
੓ͺଁ୉Ͷͯ͵͗ͮͪͳਬࡱ͠ΗΖɽ 
  ௷ ੓୉ௐԎ͹࣑ྏͶ͕͏ͱ PD ͺܲ঳͖Δ॑঳ΉͲ෱߁͚࢘ΚΗɼܲ঳Ώ஦౵঳Ͳͺ
ௐ஭Ώܨ޳Ͳɼ॑ ঳Ͳͺ੫஭Ͳ͹࢘༽΍ߨΚΗΖɽ͢ ͪ͗ͮͱɼPD ͹ްིద͵ٷफͳ࣍କͶ
ΓΕɼ౦༫ྖͳ౦༫յ਼͹ݰঙ͗غଶ͠ΗΖɽͨ͞ͲɼDSS ༢൅௷ ੓ϠυϩϜΤηͶ PD 
؜༙ΰϩΝ౦༫ͤΖࡏɼCyD ͶΓΖ PD ͹༻մ੓޴৏͕Γ;ΰϩԿͶΓΖভԿ؇಼଼ཻ੓޴
৏ͶΓΖ TmaxɼAUCɼMRT ͹ଁ୉Νߡྂ͢ɼ2ೖֶؔͲܨ޳౦༫ͪ͢ɽͨ͹݃Վɼ2ೖֶؔ
͹౦༫Ͷ΍͖͖ΚΔͥ୉ௐ͹җक़ɼ୉ௐ͹Ԏ঳Νཊ੏͢ɼ͠ΔͶɼ௷ ੓୉ௐԎ׳ंͶΊΔ
ΗΖස݄ 81) ͹րવ΍؏ࡱ͠Ηͪ (Figs. 25-27 and Table 5)ɽ͞Ηͺɼΰϩ஦͹ PD ͗ްིదͶ
ٷफʀ࣍କͪͪ͢Όͳߡ͓ΔΗͪɽ͖͢͢ɼητϫ΢χ੣ࡐͲ͍Ζ PD ͹ٷफଁ୉Ͷ൒͏෯
ࡠ༽൅ݳ͹Ϩηέ͗ߡ͓ΔΗΖɽ௪৙ɼPD ͶΓΖ࣑ྏͺɼ࿊ೖ౦༫ͶΓΕްՎΝ൅ضͤΖ͹
Ͷଲ͢ͱɼࠕյ͹ PD ؜༙ΰϩͺɼ2 ೖֶؔ͹౦༫Ͳ͍ΖͪΌɼ௪৙͹࣑ྏΓΕ΍ PD ౦༫
ͶΓΖෝ՛ͺঘ͠͏΍͹ͳਬࡱ͠ΗΖɽࣆࣰɼPD ؜༙ΰϩ౦༫ͶΓΖ݊৙܊Ґ৏͹ᡰଃҗक़
ͺ؏ࡱ͠Η͵͖ͮͪ (Table 6)ɽ͠ ΔͶɼPD ͹ྖΝ 1/5Ͷͪ͢ PD ؜༙ΰϩͲ΍ಋ༹͹୉ௐԎ

࣑ྏްՎΝ൅ضͪ͢͞ͳΝ֮೟͢ͱ͏Ζ (Data not shown)ɽॊͮͱɼPD ͹౦༫ྖΝ͠ΔͶݰ
Δͤ͞ͳͺՆ೵Ͳ͍Εɼ෯ࡠ༽൅ݳ͹ϨηέͺݰঙͤΖ΍͹ͳߡ͓ΔΗΖɽ 
ϧρφͳϐφͲͺϕϪχωμϫϱ͹େःͶ͍ࠫ͗ΕɼൔݰغͺͨΗͩΗ 1࣎ؔɼ3.5࣎ؔ


































ʀ Slow release of PD㻌
ʀ High digestive tract retention㻌
Two-day interval administration㻌
DSS㻌
DSS㻌 ʀ Suppresses colonic atrophy㻌
ʀ Anti-inflammation㻌
ʀ Anti-oxidation㻌
ʀ Improvement of anemia㻌
Treatment of DSS induced ulcerative colitis㻌
Absorption of PD 
ʀ AUC  ↑ 
ʀ MRT ↑ 
ʀ BA   ↑ 

୊ 6ઇ ঘׇ 
 
ຌহͲͺ SDACNFs ͹ҫ༂΃͹Ԣ༽Ν໪దͳ͢ͱ SDACNFs/SBE-β-CyD ΰϩ͹ DSS 
༢൅௷ ੓୉ௐԎ࣑ྏްՎͶͯ͏ͱݗ౾ͪ͢ɽҐԾͶɼಚΔΗͪஎݡΝঘׇͤΖɽ 
 
1) SDACNFs ͺ SBE-β-CyD ͳૌΊ߻ΚͦΖ͞ͳͲ؈สͶ߶کౕ͹ΰϩ͗௒੣Ն೵Ͳ͍
ͮͪɽ 
 
2) PD ؜༙ΰϩ͖Δ͹ PD ๎ड़ͺ PD/SBE-β-CyD ༻ӹͳർֳ͢ͱঅ๎੓Νࣖ͢ɼHiguchi 
ࣞͶॊͮͪϜφϨέηܗ๎ड़Ͳ͍ͮͪɽ 
 
























Ԏ঳ްՎ 4–6)ɼ߇࢐ԿްՎ 7–9)ɼࢹ࣯ٷ஥ްՎ 10,11)ɼਝฯޤްՎ 12,13)ɼ૓উ࣑༌ଇ਒ްՎ 4,14,15)
͵ʹ͠Ή͡Ή͵ਫ਼ཀྵ׈੓͗ๅࠄ͠Ηͱ͕ΕɼΫφγϱͶ؜ΉΗΖΠϝόخ͹ଚࡑ͗॑གྷͲ͍
Ζɽ 
  ۛ೧ɼΩω༟པ͹ΫοϱΝ࣬ࣞฆࡇͤΖ͞ͳͲψόϓΟ΢ώʖԿͪ͢ CNFs ͗֋൅͠Ηɼ





  Ήͥɼ୊ 2 হͲͺɼSDACNFs ͹ୱಢ͹ްՎΝ CRF Ϡυϩϧρφ ͶԢ༽͢ɼͨ͹ਝฯ
ޤްՎͶͯ͏ͱɼྡজͲ࢘༽͠Ηͱ͏Ζ AST-120 (έϪϟζϱ®) ͳർֳݗ౾ͪ͢ɽ࣏Ͷɼ୊
3হͲͺɼSDACNFs Ν౜݃ף૫ͤΖ͞ͳͲηϛϱζয়ͶՅ޽͢ɼͨ ͹૓উ࣑༌ଇ਒ްՎͶͯ
͏ͱɼྡজͲ࢘༽͠Ηͱ͏ΖΫοϱ༟པ૓উඅ෶ࡒͲ͍ΖϗηΫοϱ®ͳർֳݗ౾ͪ͢ɽ୊ 4
হͲͺɼΩοΨϱ੓͹ SDACNFs ͳΠωΨϱ੓͹ SBE-β-CyD ΝૌΊ߻ΚͦΖ͞ͳͲ߶کౕ
͹ΰϩΝ௒੣͢ɼ͠ ΔͶɼCyD ͹࣍ͯೋਭ༻੓༂෼༻մްՎΝཤ༽͢ͱɼೋਭ༻੓༂෼͹ PD 
Ν؜༙ͪ͢ PD ؜༙ΰϩΝ௒੣ͪ͢ɽ࣏Ͷɼ͞͹ PD ؜༙ΰϩΝ DSS ༢൅௷ ੓୉ௐԎ࣑
ྏ΃Ԣ༽ͪ͢ɽҐԾͶɼຌݜڂͲಚΔΗͪஎݡΝ૱ׇͤΖɽ 
 
1) 5/6 ਝଃఢड़ϧρφͶ͕͜Ζ SDACNFs ͹ਝ෈સ਒ߨ͕Γ;࢐ԿηφϪη͹ཊ੏ͶؖͤΖ
ݗ౾ (୊ 2হ) 
 
  ਝ෈સͺɼৱࣆ஦Ͷ؜ΉΗΖ΢ϱχʖϩ͗ভԿ؇ΓΕٷफޛɼ،ଃͶͱ IS Ͷେः͠Ηɼ

ͨ͹ IS ͗ட੷ͤΖ͞ͳͲϧζΩϩΝӀً͘͢͞ѳԿͤΖɽͨ ͞ͲɼSDACNFs ͹ in vitro Ͷ
͕͜Ζ΢ϱχʖϩٷ஥೵Ν඲Ճͪ݃͢Վɼ୦ΠιοϩԿౕ͹ఁ͏ (༁ 1 %) CNFs ΓΕ΍߶͏
ٷ஥Νࣖͪ͢͞ͳ͖ΔɼΫοϱ͕Γ;Ϋφγϱ͹΢ϱχʖϩٷ஥ͶͺɼΠϝόخ͹ଚࡑ͗॑
གྷͲ͍Ζ͞ͳ͗ࣖ͠ΗͪɽΉͪɼSDACNFs ͳಋͣ୦ΠιοϩԿౕͲ͍Εɼ࣬ࣞฆࡇ͢ͱ͏
͵͏ψόϓΟ΢ώʖݬྋͲ͍Ζ DAC (୦ΠιοϩԿౕ 20 %) ΓΕ΍༑Ηͪٷ஥ްՎΝࣖ͢
ͪɽ͞ΗͺɼψόϓΟ΢ώʖԿͶΓΖ෾ࢆ੓͹޴৏͕Γ;න໚੷͹ଁ୉ͶًҾͤΖͳߡ͓Δ
ΗΖɽ࣏Ͷɼ5/6 ਝଃఢड़ͪ͢ CRF ϠυϩϧρφͶ SDACNFs Ν 4 ुؔຘೖܨ޳౦༫ͪ͢
݃ՎɼSDACNFs ͺɼࢤ൤͹ອ੓ਝ෈સ࣑ྏ༂Ͳ͍Ζ AST-120 (έϪϟζϱ®) ΓΕ΍΢ϱχ
ʖϩٷ஥ྖ͗ঙ͵͏Ͷ΍ؖΚΔͥɼAST-120 ΓΕ΍ BUNɼέϪΠοωϱɼໃؽϨϱɼIS ೳ




















3) ϕϪχωμϫϱ (PD) ؜༙ SDACNFs/ηϩϙϔοϩΦʖτϩ-β-εέϫυΫηφϨϱ 
(SBE-β-CyD) ΰϩ (PD؜༙ΰϩ) ͹ DSS ༢൅௷ ੓୉ௐԎ࣑ྏͶؖͤΖݗ౾ (୊ 4হ) 
 
  SDACNFs ͹න໚ͶଚࡑͤΖΠϝόخͶ஥໪͢ɼΩοΨϱ੓͹ SDACNFs ͶΠωΨϱ੓
Ͳ͍Ζ SBE-β-CyD ΝૌΊ߻Κͦͪ݃Վɼ߶کౕ͹ΰϩ͗௒੣Ͳ͍ͮͪɽΉͪɼͨ ͹ΰϩԿͺ
ψόϓΟ΢ώʖͶಝ༙͹ݳেͲ͍ͮͪɽ࣏ͶɼCyD ͹࣍ͯ༂෼༻մࡠ༽Νཤ༽͢ɼೋਭ༻੓
༂෼Ͳ͍Ζ PD Νΰϩ಼Ͷ෩೘ͪ݃͢Վɼ௒੣Ͷ༽͏Ζ SBE-β-CyD ೳౕғଚదͶ PD ͹෩
೘ྖ͗ଁ୉͢ɼͨ ͹ΰϩ͖Δ͹ PD๎ड़ͺɼPD/SBE-β-CyD ༻ӹͳർֳ͢ͱঅ๎੓Νࣖͪ͢ɽ
࣏Ͷɼ͞ ͹ PD ؜༙ΰϩΝϧρφ΃ܨ޳౦༫ͪ݃͢ՎɼPD/SBE-β-CyD ༻ӹͳർֳ͢ͱɼAUC 
ΏMRT ͹ଁ୉֮͗೟͠Ηͪɽ͞ ΗͺɼSDACNFs ͹ΰϩԿͶΓΖভԿ؇಼଼ཻ੓޴৏ͶًҾ
ͤΖ͞ͳΝ MRI ͕Γ;ΦώϱηϔϩʖΝ༽͏ͪভԿ؇؏ࡱͶΓΕ֮೟ͪ͢ɽPD ؜༙ΰϩΝ 
DSS ༢൅௷ ੓୉ௐԎϠυϩϜΤηͶ 2ೖֶؔͲܨ޳౦༫ͪ݃͢ՎɼভԿ؇಼଼ཻ੓޴৏Ͷ




















DM-β-CyDɼHexadecyltrimethylammonium bromide (HTAB) ͺψΩϧ΢τηέ͖Δ߬೘ͪ͢ɽ
SBE-α-CyDɼSBE-β-CyDɼSBE-γ-CyD ͺ Ligand Pharmaceuticals ऀ͖Δܛ༫͠Ηͪ΍͹Ν࢘༽
ͪ͢ɽϜήϋϑηφ੫஭® (Meglumine Gadopentetate, Gd-DTPA) ͺώ΢Φϩ༂඾͖Δ߬೘ͪ͢ɽ
DSS (36-50kDa) ͺ MP Biomedicals ऀ͖Δ߬೘ͪ͢ɽProtein Quantification Kit-Wide Rangeɼ
EDTAō2K (Ethylenediamine-N,N,N',N'-tetraacetic acid, dipotassium salt, dihydrate) ͺಋਖԿָݜڂ
ॶ͖Δ߬೘ͪ͢ɽοΨʖϩητʖνη଎ఈΫρφͺೖຌδ΢ϩೖຌ࿟Կ੏ޜݜڂॶ͖Δ߬೘









1. SDACNFs ͹௒੣ 29) 
ࣰݩͶ࢘༽ͪ͢ SDACNFs ͺɼ௙ख୉ָ୉ָӅ޽ָݜڂՌ ґෳ ৵ղ ०گदͶ఑ڛ͢
ͱ͏ͪͫ͏ͪ΍͹Ν࢘༽ͪ͢ɽҐԾͶ௒੣๑Νىͤɽ 
ΠϩβϱฉҕـԾɼΫοϱฆ຦ 30 g Ν 20 % ਭ࢐ԿψφϨΤϞਭ༻ӹ 3.0 ̣ ஦Ͳ 20

࣎ؔؒླྀͪ͢ɽ৏ੜΝखΕঈ͘ɼ௞ా෼Νৢཻਭͳ 0.5 % ਥ࢐ਭ༻ӹͲજ৞ͪ͢ɽԗৼ෾཯
ͶΓΕɼਭ༻੓ਫ਼੔෼ (ਭ࢐ԿψφϨΤϞɼਥ࢐ψφϨΤϞɼΠϩΩϨॴཀྵͶΓΕՅਭ෾Կ͢
ͪΫοϱ) Νঈڊͪ͢ɽ௒੣ͪ͢୦ΠιοϩԿΫοϱΝ 4.0 L ͹ਥ࢐ਭ༻ӹͶ෾ࢆͦ͠ɼή
ϧ΢ϱξʖॴཀྵ (ଁ߀ࢊۂ੣ɼMKCA6-3) Νͪ͢ɽ௒੣ͪ͢ SDACNFs ͹୦ΠιοϩԿౕͺ 
20 %ɼฑۋ෾ࢢྖͺ 60000 Da Ͳ͍Ζɽ 
 
2. ಊ෼ࣰݩ 
CRFϠυϩϧρφͳ͢ͱɼ5/6 ਝଃఢड़ Wister ܧ༦੓ϧρφ (140-150 g) ΝೖຌΦηΦ
ϩεʖΓΕ߬೘ͪ͢ɽ 
৏ى͹ϧρφΝඉ౦༫܊ɼDAC ౦༫܊ɼSDACNFs ౦༫܊ɼAST-120 ౦༫܊Ͷ෾ྪͪ͢ɽ
ࢾݩغؔ஦ (4ुؔ)ɼࣄྋͳਭͺࣙ༟ઃखͳ͢ɼ֦ ౦༫܊Ͷͺɼ֦ γϱϕϩΝ 40 mg/kg/dayͲ
μϱυΝ༽͏ͱܨ޳౦༫ͪ͢ɽ౦༫࣎ࠃͺɼ17࣎ͳͪ͢ɽ 
 
3. ݄ᕸ஦ IS ͹ఈྖ 
ࣰݩ֋࢟࣎ (0ु) ͳࣰݩ֋࢟ 4ुޛͶϧρφඎ੫ຼ͖ΔɼϖϏϨϱଚࡑԾͲࡀ݄Νߨͮ
ͪ (༁ 2 mL)ɽࡀख݄ͪ͢ӹΝԗৼ෾཯͢ɼ݄ᕸγϱϕϩΝಚͪ (༁ 1 mL)ɽ݄ᕸγϱϕϩͺ





ΩϧϞ ʁ Mightysil  RP-18 (5 μL)ʤؖ౨Կָʥ 
ϛϱϕ ʁ ೖཱི 655  A-11 ܗ 
ݗड़ح ʁ ೖཱི L-7480ܗܮޭݗड़ح 
Ңಊ૮ ʁ ΠιφωφϨϩʁ0.2 M ਥ࢐؉ুӹ (pH 4.5) (v/v) = 25:75 
଎ఈഀௗ ʁ ܮޭϠωνʖʤྯًഀௗ/ܮޭഀௗ = 280 nm/370 nmʥ 

ླྀଐ ʁ 1.0 mL/min 
 
4. ݄ᕸ߇࢐Կ೵ (PAO) ͹඲Ճ 
ಚΔΗ݄ͪᕸ͹߇࢐Կ೵Ν߇࢐Կ೵଎ఈΫρφʰPAOʱ(ೖݜδ΢ϩ) ͹଎ఈϕϫφαʖ
ϩͶॊ͏଎ఈͪ͢ɽγϱϕϩسएӹ 390 μL Ͷଲ͢ͱϧρφ݄ᕸ 10 μLΉͪͺඬ६෼࣯ͳ͢
ͱৢཻਭͲஊ֌سएͪ͢ 2 mM ͹೚࢐ 10 μL ΝՅ͓Ꭱ፫ͪ͢ɽϜ΢έϫϕϪʖφͶ 200 μL/
ΤΥϩ෾஭ޛɼ490 nm Ͷ͕͜ΖٷޭౕΝ଎ఈͪ͢ɽ֦ΤΥϩͶ Cu++ ࢾ༂ 50 μL ෾஭͢ɼ࣪
ԻͲ̑෾ؔ΢ϱΫϣϗʖφͪ͢ɽ֦ΤΥϩ͹ൕԢంࢯӹΝ 50 μL ෾஭ޛɼ490 nm Ͷ͕͜Ζ
ٷޭౕΝ଎ఈͪ͢ɽൕԢ઴ޛ͹ٷޭౕ͖ࠫΔ݄ᕸγϱϕϩ͹೚࢐૮౲ྖ (mM) Νࢋड़͢ɼ
2189 (೚࢐ 1 mM = 2189 μmol/L (Cu ؒݫྙ)) Νֽ͜ͱ PAO ͳͪ͢ɽٷޭౕͺ TECAN ੣ 
infinite M200 PRO Ν༽͏ͱ଎ఈͪ͢ɽ 
 
5. ਝଃૌ৭ָద؏ࡱ 
ࢾݩश྅࣎͹ϧρφ͹ਝଃ͹ 10 % ஦੓؉ুϙϩϜϨϱਭ༻ӹͲݽఈޛɼϏϧϓΡϱใ
ດ઀ฤ (2.5 μm) Νࡠ੔͢ɼPASઝ৯ (Periodic acid Schiff stain)ɼMasson’s trichrome ઝ৯ɼ8-
OHdGઝ৯Νߨͮͪɽܮޭݨඏں (Keyence ੣ɼBZ-X700) Ͷͱૌ৭ժ଀Νखಚͪ͢ɽ 
 
6. ΢ϱχʖϩٷ஥೵඲Ճ 
֦ೳౕ͹ٷ஥ࡒΝ 16.7 μmol/L ΢ϱχʖϩਭ༻ӹ஦Ͳ 1࣎ؔΉͪͺ 24࣎ؔ΢ϱΫϣϗʖ
φͪ͢ɽ༻ӹ͹ΘգΝߨ͏ɼΘӹ஦͹΢ϱχʖϩ (ٷफۅ୉ഀௗʁ270 nm) Ν UVݗड़ح (ೖ







ʀʀʀʀʀ(1) q = 1 + KC 
qmKC 

ࣞ (1) ͹ྈวΝ C ͲׄΕɼٱ਼ϕϫρφΝߨͮͪɽͨ͹௜ત͹ܑ͕͘Γ;઀ฤ͖Δ qm 




















1. SDACNFs ͹௒੣ 
୊ 2হͳಋ༹͹๏๑Ͳ SDACNFs Ν௒੣ͪ͢ɽ 
 
2. SDACNFs ηϛϱζ͹௒੣ 
ௗ๏ܙ͹ܗ (ԥ 20 mmɼԠߨ͘ 30 mmɼ߶͠ 15 mm) Ͷ SDACNFs 3.5 g ΝՅ͓ɼྮ ౜ޛɼ
౜݃ף૫ (EYELA ੣ɼFDU-1200) Νߨͮͪɽ 
 
 
3. ಊ෼ࣰݩ 83) 
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C + qmK 
1 






ࢾݩश྅࣎͹ϧρφ͹ൿේૌ৭Ν 10 % ஦੓؉ুϙϩϜϨϱਭ༻ӹͲݽఈޛɼϏϧϓΡ




ుѻ 15 kV Ͳ؏ࡱͪ͢ɽ 
 
6. ંৰֱ଎ఈ 
  ֦γϱϕϩΝԾى͹ড়݇Ͷॊ͏ཀྵݜؽփ੣ P-16B घಊϛϱϕͲѻक़ܙ੔ͪ͢ 
  
γϱϕϩྖʁ 30 mg 
ѻྙ   ʁ 20 MPa 
ѻक़࣎ؔ ʁ 5 min 
௜ܚ   ʁ 10 mm 
 
  ѻक़ܙ੔ͪ͢γϱϕϩ৏෨ΓΕεϨϱζ઎୼͹ਭథ (1 μL) Νγϱϕϩ໚Ͷંৰͦ͠ɼ1
භֶؔͲ 10භؔ͹ંৰֱΝڢ࿪ֆ໚Ռָ੣ ̛̤-501 Ν༽͏ͱ଎ఈͪ͢ɽ 
 
7. ٷਭྖ଎ఈ 









1. SDACNFs ͹௒੣ 
  ୊ 2হͳಋ༹͹๏๑Ͳ SDACNFs Ν௒੣ͪ͢ɽ 
 
2. SDACNFs/SBE-β-CyD ΰϩ͕Γ; PD ؜༙ΰϩ͹௒੣ 
  ௜ܚ 12 mm͹ԃ౷Ͷ SDACNFs 1 g ΝՅ͓ɼͨ͹৏͖Δ SBE-β-CyD ༻ӹ 1 mLΝ 24࣎








 ͦΞஇଐౕʁ 0.1 – 1000 s-1 
 Իౕ   ʁ 25 oC 
 
4. ༻ड़ࢾݩ 
  Ծى͹ড়݇Ͷॊ͏෍ࢃࢊۂ੣  NTR-6100 DISSOLUTION TESTER ͕Γ;  AUTO 
SAMPLER-Wɼౣ ௣੣ࡠॶ੣ UV-1600 UV-VISIBLE SPECTROPHOTOMETER Ν༽͏ͱߨͮͪɽ 
 
ࢾݩ๏๑ʁյ఺ώηίρφ๑ 
ࢾݩӹ ʁ୊ 16ۃ ೖຌ༂ۃ๏ ୊ 1ӹ͕Γ;୊ 2ӹ 
ࢾݩӹྖʁ450 mL 
յ఺਼ ʁ50 rpm 









n = 1͹࣎ʁ0࣏๎ड़Ͷͪ͗͑͢๎ड़ 
 
 
n = 0.5͹࣎ʁHiguchi ࣞͶͪ͗͑͢๎ड़ 79)  
 
 
֦͕࣎ؔΓ;֦࣎ؔ͹ 0.5৒Ͷଲ͢ͱ๎ड़ིΝϕϫρφͪ͢ɽͨ ͹௜ત͹ܑ͖͘Δ K0 ͕
Γ; r2 Νࢋड़ͪ͢ɽ 
 
5. PD ؜༙ΰϩ஦͹ PD͹ର಼ಊସࢾݩ 
1 mLεϨϱζ಼Ͷ SDACNFs 0.8 mL ͕Γ; PD/10 % SBE-β-CyD ༻ӹ 0.2 mL ΝՅ͓ɼ
ΰϩΝ௒੣ͪ͢ɽΉͪɼαϱφϫʖϩͳ͢ͱಋͣ༽ྖͲ௒੣ͪ͢ PD ݔ୛ӹɼPD/SDACNFs 
ࠠ߻෼ɼPD/SBE-β-CyD ༻ӹΝ༽͏ͪɽ۟ಊΓΕ߬೘ͪ͢ SD ϧρφ (7ुྺɼ༦੓) ΝҲ൫
ઊৱޛɼ PD ͳ͢ͱ 8 mg/kg Ͷ͵ΖΓ͑Ͷ௒੣֦ͪ͢γϱϕϩΝμϱυͶΓΕܨ޳౦༫ޛɼ
ϖϏϨϱॴཀྵͪ͢εϨϱζͲܨ࣎దͶࡀ݄ (༁ 200 μL) Νߨ͏ɼԗৼ෾཯ޛɼ݄ᕸΝյफ͢




ݗड़ح          ʁೖຌ෾ޭ੣ JASCO UV-2075 plus 
ϛϱϕ          ʁೖຌ෾ޭ੣ JASCO PU-2089 plus 
ΩϧϞΨʖϔϱ  ʁೖຌ෾ޭ੣ JASCO 860-CO 
Q (%) = K0ʀt 
n
 
Q (%) = K0ʀt  
Q (%) = K0ʀt 
0.5 
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Ψʖφγϱϕϧʖʁೖຌ෾ޭ੣ JASCO AS-2055 plus 
ླྀଐ            ʁ1 mL/min 
Ңಊ૮          ʁ0.1 %φϨϓϩΨϫਥ࢐؜༙ 26 % 2-ϕϫϏόʖϩਭ༻ӹ 
ΨʖϔϱԻౕ  ʁ40 ˈ 
஭೘ྖ     ʁ80 μL 
଎ఈഀௗ    ʁ246 nm 
 
6. MRI ͶΓΖভԿ؇಼଼ཻ੓඲Ճ 
1 mLεϨϱζ಼Ͷ SDACNFs 0.2 mL ͕Γ; Gd-DTPA/ 10 % SBE-β-CyD ༻ӹ 0.05 mL 
ΝՅ͓ɼΰϩΝ௒੣ͪ͢ (Gd-DTPA ͳ͢ͱ 0.5 mM ؜༙)ɽೖຌΦηΦϩεʖΓΕ߬೘ͪ͢ 
ddY ϜΤη (4 ुྺɼ༦੓) ͶΰϩΉͪͺಋೳౕ͹ Gd-DTPA Ν؜༙ͪ͢ਭ༻ӹΝܨ޳౦༫




T1-weighted multi-slice images were obtained with a fast spin-echo  
sequence repetition time ʁ450 ms 
echo time ʁ13 ms 
number of excitations ʁ2 
slice thickness ʁ2 mm 
field of view  ʁ30 mm ʹ 60 mm 
image resolution  ʁ128 ʹ 256 
 
7. ΦώϱηϔϩʖͶΓΖভԿ؇಼଼ཻ੓඲Ճ 
SDACNFs 0.8 mL Ͷଲ͢ͱΦώϱηϔϩʖ 1 mg ͳ͵ΖΓ͑Ͷࠠ߻͢ɼ10 % SBE-β-CyD 





8. PD ؜༙ΰϩͶΓΖ DSS ༢൅௷ ੓୉ௐԎ࣑ྏްՎ 
௷ ੓୉ௐԎϠυϩϜΤη 72) ͺɼೖຌΦηΦϩεʖΓΕ߬೘ͪ͢ sea-ICR ϜΤη (7ु
ྺɼ༦੓) Ͷ 3 % DSS ਭ༻ӹΝຘೖࣙ༟Ӂਭͦ͠Ζ͞ͳͲࡠ੔ͪ͢ɽ୉ௐԎ঳য়͗ड़࢟Όͪ
3 ೖ໪ΓΕɼʰ 5. PD ؜༙ΰϩ஦͹ PD ͹ର಼ಊସࢾݩʱͶ༽͏ͪγϱϕϩ͹ 1/5 ηίʖϩ
͹ PD ݔ୛ӹɼPD/SBE-β-CyD ༻ӹɼPD/SDACNFs ࠠ߻෼ɼPD/SDACNFs/SBE-β-CyD ΰϩ 
(PD౦༫ྖͳ͢ͱ 10 mg/kg) Ν 2ೖֶؔͲܨ޳౦༫ͪ͢ɽࣰ ݩ֋࢟ 8ೖ໪ͶϜΤηΝṌࡶ͢ɼ
֦඲ՃΝߨͮͪɽ 
 
9. ୉ௐૌ৭ָద؏ࡱ 85) 
  ࢾݩ֋࢟ 8 ೖ໪͹ DSS ༢൅௷ ੓୉ௐԎϠυϩϜΤη͹୉ௐΝఢड़͢ɼϙϩϜϨϱͲ
ݽఈޛɼϏϧϓΡϱใດ઀ฤ (4 μm) Νࡠ੔͢ɼHE ઝ৯Νߨͮͪɽͨ͹ޛɼܮޭݨඏں 
(Keyence ੣ɼBZ-X700) Ͷͱૌ৭ժ଀Νखಚͪ͢ɽ 
 
10. ୉ௐϝΦϫϘϩΨΫεξʖκ (MPO) ׈੓଎ఈ 86) 
  ࢾݩ֋࢟ 8 ೖ໪͹ DSS ༢൅௷ ੓୉ௐԎϠυϩϜΤη͹୉ௐΝఢड़͢ɼఢड़ͪ͢୉ௐ
Ͷ 0.5 % HTAB/50 mM Ϩϱ࢐ΩϨΤϞ؉ুӹ (pH 6.0) ΝՅ͓ɼϙϠζψ΢δʖ (Ϝ΢έϫτ
ρέʀωοΨϱ੣ɼRHYSCOTRON) ͲϙϠζψ΢θͪ͢ɽ20භؔ͹௔Խഀॴཀྵޛɼӹର஢ો
Ͳॢؔྮ౜ॴཀྵ͢ɼ࣪ԻͲ͹༧մΝ 3յߨͮͪɽ4 ˈɼ10,000 g Ͳ 10෾ؔԗৼޛɼ৏ੜΝյ
फͪ͢ɽo-Dianisidine Ԛ࢐Ԛ 0.167 mg/mL (50 mM Ϩϱ࢐ΩϨΤϞ؉ুӹ) 200 μL Ͷγϱϕ
ϩ 10 μL ͕Γ; 50 mM Ϩϱ࢐ΩϨΤϞ؉ুӹͲسएͪ͢ 0.1 % գ࢐Կਭોਭ༻ӹΝ 10 μL 
Յ͓ɼϕϪʖφϨʖξʖ (TECAN੣, infinite M200 PRO) Ͳܨ࣎దͶ 460 nm Ͷ͕͜Ζٷޭౕ
Ν଎ఈͪ͢ɽΉͪɼγϱϕϩ͹νϱϏέྖͺɼProtein Quantification Kit-Wide Range Ν༽͏ͱ
ϕϫφαʖϩͶॊ͏଎ఈͪ͢ɽνϱϏέྖึਜ਼͍ͪ࣎ؔͪ͢Ε͹ٷޭౕรԿ (᷐OD/minʀmg 

protein) Ν MPO ׈੓ͳͪ͢ɽ 
 
11. ݄ځϏϧϟʖν͹଎ఈ 
  ࢾݩ֋࢟ 8ೖ໪͹ DSS ༢൅௷ ੓୉ௐԎϠυϩϜΤη͖Δ EDTAō2K ॴཀྵͪ͢εϨϱ




  ࢾݩ֋࢟ 8ೖ໪͹ DSS ༢൅௷ ੓୉ௐԎϠυϩϜΤη͖Δ EDTAō2K ॴཀྵͪ͢εϨϱ
ζͲࡀ݄ (༁ 0.5 mL) Νߨ͏ɼԗৼ෾཯ޛɼ݄ᕸΝյफͪ͢ (༁ 200 μL)ɽ݄஦͹οΨʖϩ؜
ྖͺɼοΨʖϩητʖνη଎ఈΫρφΝ༽͏ͱϕϫφαʖϩͶॊ͏଎ఈͪ͢ɽ֦ΤΥϩͶϜ
Τη݄ᕸ 20 μL Ήͪͺ calibrator 20 μL ΝՅ͓ɼReaction buffer A 200 μL ΝՅ͓ͪɽ405 nm 
Ͷ͕͜ΖٷޭౕΝ଎ఈͪ͢ɽ֦ΤΥϩͶ Reaction buffer B 20 μL Յ͓ɼ37 oC Ͳ 30෾΢ϱΫ
ϣϗʖφͪ͢ɽ405 nm Ͷ͕͜ΖٷޭౕΝ଎ఈ͢ɼൕԢ઴ޛ͹ٷޭౕࠫ (᷐OD) ͖ΔԾى͹ࣞ
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  ຌݜڂͶࡏ͢ɼश࢟ޜࠛಠ͵Ζޜࢨ಍ͳޜ佅ᎬΝࣂΕΉͪ͢਺৕୉ָ༂ָ෨ ੣ࡐָݜڂ ࣪
ฑࢃ ชय़ گदɼ҈ֺ ੥ گदͶ਄ਛ͵Ζ״ः͹қΝන͢Ήͤɽ 
 
  ຌݜڂΝߨ͑Ͷࡏ͢ͱ༙ӻ͵Ζޜࢨ಍ͳޜ佅ᎬΝࣂΕΉͪ͢਺৕୉ָ༂ָ෨ ੣ࡐָݜڂ ࣪
ݫگद ৏佄 ݋ਕ ઎ਫ਼ɼ҉ݬ ୉ื ߪࢥͶ਄ਛ͵Ζ״ः͹қΝන͢Ήͤɽ 
 
  ຌݜڂΝߨ͑Ͷࡏ͢ɼଡ୉͵Ζ͟ঁྙΝࣂΕΉͪ͢਺৕୉ָ༂ָ෨ ༂෼ಊସָݜڂ࣪
ঘీ઀ ༑ध گदɼۿຌ୉ָ༂ָ෨ ༂ࡐָ෾໼ ؛ࢃ బ گदͶ਄͚״ः͹қΝන͢Ή
ͤɽ 
 
  ຌ࿨ช͹৻ࠬͶ͍ͪΕɼ༙ӻ͵ޜঁݶͳޜߏԀΝࣂΕΉͪ͢਺৕୉ָ༂ָ෨ ݬ෤ Ӷ گदɼ
໵࿮ ୉ղ گदͶ਄͚״ः͹қΝන͢Ήͤɽ 
 
ຌݜڂͶࡏ͢ɼΫοϱψόϓΟ΢ώʖ͵Δ;Ͷන໚୦ΠιοϩԿΫοϱψόϓΟ΢ώʖ
Ν఑ڛ͢ͱ͏ͪͫ͘Ήͪ͢௙ख୉ָ୉ָӅ޽ָݜڂՌ ґෳ ৵ղ ०گदͶ਄͚״ः͹қ
Νන͢Ήͤɽ 
 
ຌݜڂ͹ಊ෼ࣰݩͶࡏ͢ɼ͟ڢྙ௘͘Ήͪ͢௙ख୉ָ೸ָ෨ڠಋॏҫָՌ Ԯຌ ๗੘ گदɼ
౨ ࿪ਫ਼ ঁگͶ਄͚״ः͹қΝන͢Ήͤɽ 
 
ຌݜڂ͹  MRI ଎ఈͶࡏ͢ɼ͟ڢྙ௘͘Ήͪ͢਺৕୉ָ༂ָ෨ ෾ੵԿָݜڂ࣪
஝Ծ  ܔ଄ گदɼԮ࡜ ষࢢ ߪࢥͶ਄͚״ः͹қΝන͢Ήͤɽ 
 
ຌݜڂͶ͟ڢྙ௘͘Ήͪ͢௙ख୉ָ୉ָӅ޽ָݜڂՌ ચ ྒྷଢ࿢ र࢞ɼ௙ख୉ָ೸ָ෨
ڠಋॏҫָՌ ଡ೴  ཏ ࢱɼ਺৕୉ָ༂ָ෨ ੣ࡐָݜڂ࣪ ୉ٳฯ  চಛ ָ࢞ɼ
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